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ABSTRACT 
The rodent model is often used to study the impact of dietary n-3 fatty 
acids on a variety of biological endpoints, and the results of these studies have 
been used to explain anticipated effects of n-3 fatty acid intake in humans. 
However, supplemental levels of n-3 fatty acids that are commonly used in 
rodent studies do not represent reasonable human intake, by comparison. 
Currently there is no standard method for the addition of n-3 fatty acids to rodent 
diets. We tested a mathematical model for dosing supplemental levels of a­
linolenic acid (ALA) and eicosapentaenoic acid (EPA) to rodent diets on the basis 
of energy%. C57BI/6J mice were fed a background diet that modeled typical 
Western intake in both macronutrient and fatty acid composition. Three levels of 
ALA and EPA (0.3, 0.8, and 1.4 energy%) were supplemented to either a normal­
ALA control diet (0.6 energy% ALA) or a high-ALA control diet ( 1.2 energy% 
ALA). Plasma and erythrocyte phospholipid fatty acid changes were determined 
and compared to archival human n-3 fatty acid supplementation studies reporting 
the same tissue endpoints. In mice, supplemental EPA had a greater effect than 
supplemental ALA on both plasma and erythrocyte phospholipid EPA. 
Docosahexaenoic acid (DHA) levels in mice were only minimally changed by 
either ALA or EPA supplementation. Use of the high- ALA control diet resulted in 
attenuated phospholipid fatty acid changes in both tissues compared to the 
normal-ALA control diet for both supplemented fatty acids. At each 
supplemented dose of ALA or EPA, changes in murine plasma or erythrocyte 
V 
phospholipid EPA exceeded changes observed in the same human tissues by 
2-4 fold when compared to equivalent human supplemental doses in energy%. 
Tissue changes observed using the high-ALA control diet better modeled the 
results observed in humans at the same supplemental energy% for both ALA and 
EPA in plasma and erythrocyte phospholipids. This is the first study to use 
pharmacodynamic modeling to compare the effect of supplemental n-3 doses on 
mouse and human endpoints. The addition of n-3 fatty acids to rodent diets on 
the basis of energy% represents a reasonable improvement to current dosing 
strategies. This data is useful both as a guideline for n-3 fatty acid dosing in 
rodent studies and as a reference point for future calculated refinements in 
dosing. 
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1 REVIEW OF THE LITERATURE 
1.1 Introduction 
1 
The generation of information regarding omega-3 (n-3) fatty acids has 
been prolific over the past thirty years subsequent to Dyerberg and Bang's 
discovery in 1 971 attributing heart disease incidence reduction in Greenland 
Eskimos to their consumption of polyunsaturated fatty acids, particularly n-3 fatty 
acids (1 -3). Data obtained from both animal studies and human clinical trials 
have been used to examine the mechanisms by which n-3 fatty acids convey 
health benefits and to make judgments about optimal dietary intake levels for 
general health and disease prevention. Although much knowledge has been 
gained, there are still several questions that have not been fully addressed. The 
following project grew out of a need for empirical data to address three primary 
questions: 
1 .  What is the difference in biological impact between terrestrial n-3 fatty 
acid, cx-linolenic acid (1 8:3 n-3; ALA), and long- chain n-3 fatty acids 
(LCn3), eicosapentaenoic acid (20:5 n-3, EPA) and docosahexaenoic acid 
(22:6 n-3, DHA)? 
2. What is the impact of terrestrial or LCn3 in mice when given at levels that 
are comparable to human supplemental intake? 
3. What methodological improvements can be made in the dosing of n-3 fatty 
acids in rodent studies that allows for a more direct comparison of mouse 
and human data and a standardization of dosing across different research 
studies using animals? 
2 
1.2 Overview of Omega-3 Fatty Acids 
Description 
N-3 fatty acids are polyunsaturated hydrocarbon chains in which the first 
double bond occurs at the third carbon from the methyl end of the molecule (4). 
The three predominant dietary n-3 fatty acids are: ALA, EPA, and DHA (Figure 
1-1 ). The unique structure of n-3 fatty acids predicts, in part, their biological fate. 
Methylene-interrupted double bonds present within n-3 fatty acids make them a 
vulnerable target for hydrogen abstraction by reactive oxygen species due to 
both weakened carbon-hydrogen bonding at the methylene groups and to 
structural potential for radical stabilization via resonance (4 ). 
Dietary sources 
ALA is an n-3 fatty acid of plant origin that is consumed primarily in the 
form of vegetable oils such as canola oil (9.3% ALA by weight) and soybean oil 
(6.8 % ALA by weight) (5). Other significant sources of ALA include walnuts, 
flaxseeds, flaxseed oil, soybeans, soybean oil, and wheat germ (Table 1-1 ). EPA 
and DHA are often called the "marine" n-3s because they are present in the 
highest concentration in fatty fish such as mackerel, herring, salmon, tuna, trout, 
and halibut (6). There are also a variety of oil capsule supplements on the 
market that contain varying concentrations of EPA and DHA (and !n some cases, 
other polyunsaturated fatty acids as well). 
CHaCOOH 
18: 3 n-3, exrUnoleric acid 
H3 
20:5 n-3. Eicosapentaenoic acid 
22: 6 n-3, Docosat-exaenoic acid 
3 
Figure 1-1: Structure and nomenclature of the three predominant n-3 fatty acids 
· found in the Western diet. 
Table 1-1 
Alpha-linolenic acid content of selected food sources (5). 
Food Source 
Canola oil 
Flax seeds 
Flax seed oil 
Soybeans 
Soybean oil 
Walnuts (English) 
Wheat Germ 
ALA content (wt%) 
9.3 
1 8.1 
58 
1 .3 
6.8 
9.1 
0.72 
4 
Western consumption 
Kris-Etherton, et al. (6) report that the average daily intake of all n-3 fatty 
acids in the United States is -1.6 grams (or 0.7 energy% based on a 2000 
calorie diet). The average U.S. consumption of ALA is 1.1-1.4 grams per day 
(0.5-0.6 energy%) (6, 7). Soybean oil and canola oil are the most prevalent ALA 
sources in the U.S. diet (6). The remaining portion of average daily n-3 intake 
comes from roughly 75 mg EPA and 125 mg DHA for a total of-200 mg LCn3 
(0.09 energy%) (6-8). According to the 1999-2000 National Health and Nutrition 
Examination Survey data, the most frequently consumed fatty fish in the United 
States were tuna and salmon (9, 10). 
Recommendations for consumption 
At present, there is insufficient data necessary to establish a Recommended 
Dietary Allowance for ALA, EPA and DHA; however, several dietary 
recommendations have been made by a variety of national and international 
health organizations (Table 1-2). Recommendations are generally subdivided by 
the following population groups: healthy adults, pregnant mothers, and coronary 
heart disease patients. In September of 2004, the United States Food and Drug 
Administration (FDA) approved a petition requesting a qualified health claim for 
foods containing EPA and DHA for the prevention of coronary artery disease 
(11 ). 
AGENCY/GROUP 
American Heart 
Association (12) 
Workshop on the 
Essentiality of and 
Intakes from Omega-6 
and Omega-3 Fatty 
Acids (13) 
International 
Society for the 
Study of Fatty 
Acids and Lipids (14) 
World Health 
Organization (15) 
TABLE 1-21 
Selected national and international omega-3 fatty acid recommendations. 
COUNTRY 
USA 
I ntemational 
International 
International 
POPULATION GROUP 
Adults 
CHO patients 
Patients with i TG 
Adults 
Pregnancy/ Lactation 
Adults 
Adults 
RECOMMENDATION 
Two servings fatty fish/ week 
Include oils rich in ALA 
-1 g EPA + DHA/ day 
2-4 gms EPA + DHA/ day 
ALA: 2.22 g/day 
EPA to be at least: 0.22 g/day 
DHA to be at least: 0.22 g/day 
DHA to be at least: 0.3 g/day 
ALA: 0.7 energy% 
(1.56 g/day; 2000 kcal) 
EPA+ DHA: at least 0.5 g/ day 
All co-3 fatty acids: 1-2 energy% 
(2.2- 4.4 g/day; 2000 kcal) 
0, 
AGENCY/GROUP 
National Heart Foundation 
of Australia (16) 
Nordic Council of 
Ministers (17) 
British Nutrition 
Foundation (18) 
Health Council of the 
Netherlands (19) 
1 Adapted from Source: (20). 
COUNTRY 
Australia & 
New Zealand 
Denmark, Finland, 
Norway, & Sweden 
United Kingdom 
The Netherlands 
TABLE 1-21 
Continued 
POPULATION GROUP 
Healthy adults and CHO patients 
Persons over 3 years of age 
Adults 
RECOMMENDATION 
ALA: 2 g/day 
At least 2 fatty fish meals/week 
All co-3 fatty acids: At least 0.5% 
(1.1 g/day; 2000 kcal) 
ALA: At least 0.2 energy% 
(0.44 g/day; 2000 kcal) 
EPA+ DHA: 0.5 energy% 
(1.1 g/day; 2000 kcal) 
Birth to 5 months 
Adults 
Pregnancy & Lactation 
ALA: 0.08 g/ kg/day 
DHA: 0.02 g/ kg/ day 
ALA: 1.0 energy% 
(2.2 g/day; 2000 kcal) 
EPA + DHA: 0.2 g/ day 
ALA: 1.0 energy% 
EPA+ DHA: 0.2 g/day 
0) 
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It reads, 
"Supportive but not conclusive research shows that consumption of EPA 
and DHA omega-3 fatty acids may reduce the risk of coronary heart 
disease. One serving of [Name of the food] provides [ ]  gram of EPA and 
DHA omega-3 fatty acids. [See nutrition information for total fat, saturated 
fat, and cholesterol content.]" 
The use of this health claim will help to encourage public consumption of LCn3 
and increase the likelihood of reaching intake recommendations. 
Digestion, absorption, and transport 
N-3 fatty acids are consumed in the form of triglycerides and 
phospholipids present in food. Phospholipids contain 85-90% fatty acids and 
triglyceride content is -95% fatty acid (21 ). As unsaturated fatty acids, ALA, EPA 
and DHA are primarily found in the sn-2 position of both triglycerides and 
phospholipids (22). N-3 fatty acids follow the same course of digestion and 
absorption as other lipid components. The mechanical churning of the stomach 
(coupled with the action of gastric lipase) is the first step in lipid digestion (22) . 
Some short and medium chain fatty acids are directly absorbed through the 
stomach wall. Longer fatty acids (all omega-3s), however, are primarily broken 
down in the small intestine. In the duodenum, bile salts from the liver, as well as 
physical hydrophobic interactions (23), help to emulsify fat droplets into 
manageable subsections, creating an increase in surface area for enzymatic 
action. Pancreatic lipase (activated by co-lipase) hydrolyzes fatty acids in the 
sn-1 and sn-3 positions on the glycerol backbone of food derived triglycerides 
8 
(24), leaving two non-esterified fatty acids and 2-monoacylglycerol. 
Phospholipase A2, also originating in the pancreas, cleaves fatty acids present in 
the sn-2 position of phospholipids, leaving a free fatty acid and a 
lysophospholipid (22) (Figure 1-2). The free fatty acids and partially digested 
acylglycerols and phosphoglycerols are transported through the hydrophilic layer 
that coats the intestinal lumen by micelles. Micelles are small groupings of 
phospholipids, free fatty acids, cholesterol, mono and diacylglycerols, and bile 
salts that act as amphipathic carriers of lipid soluble molecules to the enterocyte 
membrane surface. 
Trig lycerlde Phosphollpld 
Pancreatic Lipase activity 
Phosphol i pase � activ ity 
Figure 1-2: Targeted bo.nds of pancreatic lipase _on dietary triglyceride and 
phospholipase A2 on dietary phospholipids. 
9 
Particles of lipid digestion were at one time thought to be absorbed solely 
via passive diffusion, however, it is now believed that fat binding protein carriers 
help to mediate the transfer (25, 26). Within the enterocyte, fatty acids, 
monoacylglycerols and phosphoglycerols are reassembled into triglycerides and 
phospholipids and combined with apoprotein to be secreted into the lymphatic 
system as chylomicrons and eventually enter circulation through the superior 
vena cava. Chylomicrons are distributed in the circulation to adipose tissue for 
storage and other peripheral tissues for energy (22). Lipoprotein lipase attached 
to the endothelial wall of tissue capillaries cleaves the fatty acids in the sn-1 and 
sn-3 positions of triglycerides, in a similar fashion to pancreatic lipase. 
Monoacylglycerol lipase within the plasma membrane finishes the hydrolysis of 
2-monoacylglycerol (27) and the fatty acids are carried across the membrane via 
a fatty-acid binding protein that co-transports with sodium ions (22). Free 
glycerol and chylomicron remnants are circulated back to the liver and absorbed. 
The metabolic fate of absorbed fatty acids depends on the tissue, the fatty acid 
type, and the energy state of the individual . 
Endogenous long chain omega-3 formation 
In addition to dietary intake, a minor amount of long chain n -3 fatty acids 
are synthesized de novo from dietary ALA (Figure 1-3). Mammals lack the 
ability to desaturate fatty acyl chains beyond the Li9 carbon, making consumption 
1 0  
EPA 
DHA 
Ei cosatetraenoic aci d (20:4 n-3) 
E icosapentaenoi c acid (20: 5 n-3) 
Docosapentaenoic aci d (22 :5 n-3) 
Tetracosapentaenoic acid (24 :5  n-3) 
r 'V Peroxisomal ! I Tetracosahexaenoi c aci d (24 : 6  n-3) : retro-conversion i t I 
I I Docosahexaenoic acid (22: 6 n-3) : 
\,__ _________ ) 
Figure 1 -3 :  Enzymatic conversion of ALA to LCn3 metabolites. Conversion 
occurs on the cytosolic interface of the endoplasmic reticulum with the final two 
steps involving peroxisomal retroconversion (28-31 ). 
1 1  
of the parent compound ALA essential (32). Conversion of ALA to long chain 
metabolites takes place using enzymes found in the endoplasmic reticulum 
membrane (29-31 )  ( examined as microsomes ), with the final steps of DHA 
synthesis using peroxisomes (28). The majority of conversion takes place in the 
liver, however, the machinery for ALA desaturation has been found in a variety of 
tissues such as brain, skeletal muscle , lung, and heart (33, 34). Table 1 -3 
compares several studies where ALA conversion rates were estimated using oral 
doses of radio-labeled ALA. Most studies report less than 5% conversion from 
ALA to EPA, and overall there appears to be very little conversion to DHA. This is 
supported by a study reporting an inverse relationship between the amount of 
dietary ALA consumed and DHA in several blood fractions (35). It was 
suggested that ALA is displacing DHA from membrane PLs, which would result in 
decreased absolute DHA content in the membrane. The highest conversion 
rates were seen in a study by Burdge et al . (36), where the rate of ALA to EPA 
conversion in young women was 21 % and the conversion to DHA was 9%. 
Separating conversion rates by gender has led to the hypothesis that women 
may have a greater potential for conversion based on childbearing capacity and 
prenatal needs for DHA (36, 37). 
Several factors influence the propensity for ALA conversion to long chain 
metabolites, including: 
• The amount of ALA at a given time that is removed from conversion 
by �-oxidation (38). 
TABLE 1-3 
Comparison of estimated metabolic conversion rates of dietary a-linolenic acid to long chain metabolites. 
Author/ Source Subjects 
Emken (39), 1994 Young adult males 
Hoffman (40), 2001 Healthy males 
Pawlosky (38), 2001 Healthy adults 
Pawlosky (41), 2003 Healthy adults 
Background 
Diet 
LA- 15 g/d 
LA- 30 g/d 
Low fat 
Low omega-3 
Beef based 
Self selected 
Fish based 
Beef based 
Labeled fatty acid 
Deuterated 
LA + ALA 
C 13  ALA 
Pentadeuterated 
ALA 
Pentadeuterated 
ALA 
Percent 
Conversion to 
EPA 
8.0 ± 1.5 
3.4 ± 0.5 
0.2 ± .02 
0.2 ± 0.01 
0.10 ± 0.02 
0.19 ± 0.01 
Percent 
Conversion to 
DHA 
4.0 ± 1.6 
3.6 ± 2.0 
5.0 
0.047 
0.057 
0.018 
0.075 
TABLE 1-3 
Continued 
Percent Percent 
Background Conversion to Conversion to 
Author/ Source Subjects Diet Labeled fatty acid EPA DHA 
Burdge (42), 2002 Young men Habitual diet C 13 ALA 7.9 0 
Burdge (36), 2002 Young women Habitual diet C 13  ALA 21 9 
Burdge (43), 2003 Older men Control C 1 3  ALA 1.961 0.031 
ALA- 10g/d 2.61 0.051 
EPA+ DHA- 1.5 g/d 4.01 0.071 
1 Based on cumulative amounts of EPA or DHA as a percent of total labeled ALA + EPA + DPA + DHA. 
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• The rate and sufficiency of desaturase enzymes (Ex: Li-5 
desaturase down regulation in retinitis pigmentosa (40)). 
• The amount of linoleic acid (LA; 18:2n-6) in the diet (39, 44 ). LA 
competes with ALA for the rate limiting Li-6 desaturase enzyme. 
Delta-6 desaturase is 19 times more selective for ALA than for LA 
(45), however, the ratio of LA content to ALA content in the typical 
Western diet is 10: 1, thus presenting competitive inhibition of ALA 
conversion. 
• The absolute amount of ALA, EPA, and DHA in the diet (46-48). 
One limitation of current conversion studies is their reliance on plasma 
data. It is arguable that in tissues where DHA is particularly important (i.e. brain 
and retina), conversion rates may be greater to compensate for insufficient 
dietary DHA, and that this is not reflected in the conversion estimations from 
plasma. However, overall, the current estimates of ALA conversion suggest that 
dietary ALA intake may not be a sufficient substitute for preformed LCn3 (39), 
particularly if the benefits associated with LCn3 intake are desired. Furthermore, 
increasing ALA consumption from food sources in an attempt to maximize ALA 
conversion may yield a level of total fat intake that exceeds current dietary 
recommendations (49). 
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Critical location and timing of accumulation 
The chief residence of n-3 fatty acids in biological organisms is the sn-2 
position (50 , 51 ) of phospholipids that compose cellular and organelle 
membranes. Polyunsaturated fatty acids are usually found within phospholipids 
on the cytosolic half of the membrane bilayer (52). ALA, DHA, and EPA can all 
be found in membranes, however, ALA is almost negligible in membrane lipids 
(Table 1 in (53) & (54)) due to its propensity to be oxidized or used for other 
metabolic purposes including its use a precursor to the other n-3 acids as 
described above. The most prominent membrane n-3 is DHA followed by DPA 
and EPA (Table 1 in (53)). The two tissues that accumulate the highest 
concentration of n-3 fatty acids in the body are retinal photoreceptor rod outer 
segments (53) and neural synaptosomes (49). DHA makes up 50% of the fatty 
acid content of rod outer segment membrane in the retina and can occupy both 
the sn-1 and sn-2 positions of the these phospholipids (55), allowing for maximal 
DHA concentration. Most of the DHA found in brain and retina accumulates in 
the last trimester of pregnancy and the early part of life after birth (50, 56-58). 
Prenatal accumulation of LCn3 is complex and involves several possible 
contributing sources. Maternal blood supply to the fetus (via the placenta) is the 
main supply of all fatty acids to the growing infant and lipid transfer is a reflection 
of maternal diet as well as maternal lipid stores (50, 59). Placental specificity for 
DHA binding has been reported (60), highlighting the priority that is placed on 
DHA acquisition for the fetus. Fetal conversion of ALA to LCn3 offers another 
possible route for accumulation. Conversion has been reported in fetal brain (56, 
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61 ) and liver (51 ) .  Delta 5 and �6 desaturase enzymes have also been found in 
human placenta (33). Lastly, it has been shown in rats that amniotic flu id 
swallowed in utero may also provide ALA to the fetus as a LCn3 precu rsor (51 , 
62). 
In the initial period after birth , the infant is dependent on both body stores 
and external feeding for n-3 fatty acids . Breast milk is rich in DHA and AA (63). 
Synthetic formu las, however, were devoid of either fatty acid until 2002, when 
commercial formula companies began adding DHA and AA to their formula in an 
attempt to better mimic breast milk (64 ) . Infants receiving formula without DHA 
are dependent on conversion from ALA in formula or adipose stores to obtain 
necessary DHA. Both term and preterm infants can convert ALA to DHA (65), 
however, this source of LCn3 is l imited . Rat pup body stores of DHA have been 
shown to be a substantial source of DHA in rat brain (66), even when ALA is 
provided in the diet, suggesting that there is a preference for preformed DHA. 
This is a particu larly important discovery for the treatment of preterm infants (66), 
who may miss the adipose accu mulation associated with the later stages of 
gestation (67 , 68) resulting in a reduced reserve of DHA from adipose. 
Brain and retina are known to protectively retain DHA content (50 , 69), 
and both are resistant to dietary n-3 deprivation (53 , 70). Other membranes that 
are less dependent on stable n-3 fatty acid content such as l iver, erythrocyte, and 
plasma membranes, readi ly undergo fatty acid turnover that is a directly 
influenced by changes in dietary intake . 
1 7  
Functional use of omega-3 fatty acids in the body 
Function derived from structure 
EPA in plasma membranes is mainly used as an eicosanoid precursor 
(see below) , while DHA in membranes has a very specific structural function. 
The six double bonds of DHA impart flexibility (71 , 72), disorder (73), and free 
volume (74) to regions of high DHA concentration. Steric hindrances and 
neighboring molecules exert external forces on the acyl chains (55) of 
phospholipid molecules, influencing the thermodynamic favorability of different 
structural conformations within the membrane. Molecular simulations show that 
DHA is able to make rapid conformational changes (72), and "interconversion 
between torsional states" (73, 75), and this is how it is able to confer acyl chain 
flexibility and fluidity to membranes. The space and flexibility provided by DHA 
content impacts the activation of certain membrane embedded receptors and 
enzymes, particularly those that undergo conformational changes upon activation 
requiring space for expansion. 
In the rod outer segments of the retina, high DHA concentration 
facilitates the activation of rhodopsin and subsequent G protein-coupled receptor 
signaling that impacts the visual response (76). Anderson, et al. (77) have 
shown that the retina conserves DHA because of its importance in rhodopsin 
activation. In the event of n-3 deficiency, 22:5 n-6 accumulates in the retina in 
place of DHA (76, 78). However, even though 22:5 n-6 is almost structurally 
identical to DHA in that it lacks only 1 double bond , DHA replacement negatively 
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impacts electroretinogram measurements, implying that DHA provides a specific 
structural advantage for rhodopsin activation and vision (78). 
The structural influence of membrane DHA on G protein-coupled 
receptors may also effect the neurotransmission of dopamine, serotonin, 
norepinephrine, acetylcholine, and GABA; all of which use G protein coupled­
receptors (53). This is plausible based on the high concentration of DHA in 
synaptosmal membranes and the repeated observation that DHA concentration 
may affect psychological outcomes. It has also been shown that 
neurotransmitter reuptake may be increased by degree of membrane 
unsaturation (79) through enhancement of pinocytosis. 
Ion channels and transport proteins are also affected by n-3 fatty acid 
content in the membrane. DHA has been shown to influence potassium 
channels (80), Na+ K+-ATPase activity (81, 82), and EPA influences Na+ and 
Ca++ channels in cardiac myocytes · (83, 84 ). 
Some of the other structural characteristics that are influenced by the DHA 
content in the membrane include: 
• Lipid rafts- Lack of affinity between DHA rich regions and cholesterol 
cause cholesterol rich/ DHA poor domains to form laterally within the 
membrane (85). Formation of lipid domains compartmentalize portions of 
the membrane for specific functions (32). Raft formation may also 
influence membrane embedded protein localization (73). 
• DHA influences the speed of phospholipid flip-flops across the 
hydrophobic region within the plasma membrane(86). 
• DHA may also intercept oxidative damage that would otherwise affect 
receptors and other membrane proteins (53). 
Function derived from biological products 
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Polyunsaturated fatty acids (ex: DGLA (dihomogammalinolenic acid), AA, 
EPA, and DHA) are precursors to a diverse host of biological products including: 
prostaglandins, leukotrienes(87), thromboxanes, lipoxins(87, 88), hepoxilins, 
hydroxy and hydroperoxy compounds (89) ; and the more recently discovered: 
isoprostanes (90, 91  ), neuroprotectins (92), and resolvins (93). AA and EPA 
are the two main eicosanoid precursors which compete for sn-2 position 
placement in membrane phospholipids and subsequent cleavage for ultimate 
eicosanoid production. Phospholipid concentration of AA and EPA is a direct 
reflection of dietary intake (89). AA and EPA are substrates to several enzyme 
systems that produce eicosanoid products, such as: cyclooxygenases (COX), 
lipoxygenases (LOX), and epoxygenases (32, 94 ). Eicosanoids act as local 
hormones (23), having both autocrine and paracrine activities; they travel only 
short distances to their site of action (32, 95). This is, in part, due to their rapid 
inactivation and metabolism (96, 97). AA is a precursor to the series-2 
prostaglandins (ex: PGE2, PGl2, TXA2) and the series-4 leukotrienes (ex: LTA.t, 
LTB4, etc . .  ). EPA is a precursor to the series-3 prostaglandins (ex: PGE3, TXA3) 
and the series-5 leukotrienes (ex: LTAs, LTB5).  In general, products derived from 
EPA are less potent and exhibit a less inflammatory effect than products derived 
from AA (97). For example, platelets produce the AA derived product 
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thromboxane A2, which acts as a vasoconstrictor and stimulates platelet 
aggregation (98). If EPA is enriched in membrane phospholipids rather than AA, 
EPA will be released and used to produce thromboxane A3, which is neither a 
strong vasoconstrictor or aggregator (Figure 1-4) (98). Enrichment of 
membranes with EPA as a competitor to AA has been suggested for the 
amelioration of several pathological conditions where AA derived products elicit 
undesirable effects, such as: rheumatoid arthritis, asthma, cancer, thrombosis, 
and other conditions involving n-6 eicosanoid stimulated inflammation. 
In addition to the competitive effect between EPA and AA for enzymes 
involved in eicosanoid production, new research indicates that EPA and DHA are 
precursors to potent derivatives of their own, namely , neuroprotectins (92) and 
resolvins (93). Resolvins (short for "resolution phase interaction products") are 
produced from both EPA and DHA and have been shown to have anti­
inflammatory properties through their involvement with polymorphonuclear 
leukocytes (93) .  Neuroprotectins are derived from DHA and are believed to 
protect brain cells from 11oxidative stress-induced apoptosis" (92). 
Function derived from genetic influence 
In addition to their structural and eicosanoid functions, n-3 fatty acids have 
been shown to have substantial influence on gene expression (99). Omega-3 
fatty acids act as ligands to several nuclear transcription factors involved in 
metabolism, such as: peroxisome proliferator activated receptors (PPAR-a , -�, 
and -y) , liver X receptors (LXR-a and LXR-�), and the retinoic X receptor (RXR) 
EPA 
PGH3 
TXA3 : 
Weak Constrictor, 
Aggregator 
AA 
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TXB2 : 
Vasoconstrictor, 
Aggregator 
Figure 1 -4: Eicosanoid derivatives of EPA or AA in stimulated platelets; Series-2 
vs. Series-3 thromboxanes (98, 100). 
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(101-103). N-3 fatty acids have also been shown to influence (101) other 
transcription factors, namely, sterol regulatory binding proteins (1a, 1c, & 2) (104, 
105), nuclear factor Y (106), and hepatic nuclear factor-4 (107) (though not 
through ligand binding). The net effect of PUFA genetic influence (101) is an 
increase in the expression of enzymes involved in �-oxidation (108) [ex: acyl CoA 
oxidase (109, 110), carnitine palmitoyl transferase (111, 112), and microsomal 
CYP4A2 (110)] and a decrease in the expression of several lipogenic enzymes 
(108) [ex: fatty acid synthase (111, 113-115), acetyl- CoA carboxlase (110, 114), 
stearoyl -CoA desaturase (113, 116), and malic enzyme (111, 113)] (Figure 
1 -5) . Fatty acids are believed to effect several levels of gene expression 
including: transcription factor binding, mRNA stability, transcription rate, and 
alteration of translation products (99) [ex: nuclear factor Y(106)]. Both n-3 and 
n-6 fatty acids impact genetic expression; however, Berger et al. (117) were able 
to show, specifically, that n-3 fatty acids from fish oil lead to increased expr�ssion 
of genes favoring oxidation and decreased expression of genes favoring 
lipogenesis based on microarray measurement. Gene expression does not 
appear to be limited to LCn3. In rat brain, ALA, EPA, and DHA were shown to 
have similar influence on affected genes (118). In addition to the fatty acid effect 
on gene expression, eicosanoid products of PUFA are also a potential source of 
influence (119, 120). Mechanisms of n-3 fatty acid effect on gene expression 
are still being discovered and new findings will help to clarify what health benefits 
attributed to n-3 fatty acids are due to their genetic influence. 
PUFA 
SREBPs 
LXRs PPARs HNF-4 
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y 
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t p-Oxidation 
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Figure 1 -5: Net effect of polyunsaturated fatty acid influence on several nuclear 
transcription factors involved in lipid metabolism (101, 103, 121 ). 
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Benefits of dietary omega-3 fatty acids in humans 
Cardiovascular health 
Omega-3 fatty acids have been studied in conjunction with several 
cardiovascular health outcomes, with particular interest given to triglyceride 
reduction and sudden cardiac death. 
General CVD outcomes 
Omega-3 fatty acids have been shown to provide benefit in the risk 
reduction of several cardiovascular events and subpopulations. Fish intake and 
LCn3 intake has been shown to reduce the primary risk of all cause mortality 
(122, 123), coronary heart disease (123-125), and death due to cardiovascular 
disease (124, 126). Fish intake and LCn3 supplementation has been shown to 
provide secondary risk prevention of all cause mortality (127), death due to 
coronary heart disease (127, 128), non- fatal cardiovascular events (128, 129), 
and blood pressure reduction (129, 130). Dietary and supplemental ALA intake 
has also been implicated in the primary risk reduction of non-fatal myocardial 
infarction (131, 132), prevalence of coronary heart disease (133, 134), all cause 
mortality (134 ), and death from cardiovascular disease (131, 134 ). Secondary 
prevention from ALA intake and supplementation provided risk reduction for 
coronary deaths (� 35, 136), non-fatal myocardial infarction (128, 135, 136), and 
all cause mortality (136). In general, however, CVD benefit from ALA 
consumption is less definitive than LCn3 consumption (137). Along with 
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dietary and supplemental intake of n-3 fatty acids, the concentration of n-3 fatty 
acids in serum cholesterol esters and plasma phospholipids has been shown to 
provide risk reduction for fata l CHO (1 38, 1 39) and all cause mortality( 1 39). 
Not all studies , however, proved beneficial .  Several studies reported no 
CHO reduction from ALA intake ( 140, 1 4 1 ) or LCn3 intake (1 42-1 44) or benefit in 
risk of restenosis from LCn3 (1 45), with one study even showing an increased 
risk in all cause mortality in those patients encouraged to increase fish 
consumption (1 46). Kris-Etherton ,et al. attribute some of the inconsistency of 
outcomes across these stud ies to d ifferences in the way card iac events were 
defined , differences in the populations studied ,  d ifferences in the measurement 
of fish intake, or simply variabil ity in study design (1 47). 
Stroke 
The effect of omega-3 fatty acids on risk of stroke remains unclear. The 
etiology of this connection is also unclear, though the anti-thrombotic potential of 
LCn3 (via a shift in eicosanoid production) is l ikely a contributing factor. Several 
studies report a decreased risk based on fish intake or supplemental EPA + OHA 
(1 23, 148, 1 49), with one study showing an impact divide in gender with no effect 
in men , but a reduction in stroke risk in women who ate fish at least once per 
week (1 42). ALA intake has also been shown to decrease stroke risk (1 32 , 1 35, 
140). On the contrary, many studies have also reported either no benefit from 
fish intake ( 143, 1 50) or a trend toward an increased risk of stroke based on fish 
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intake (1 50) or supplementation with EPA + DHA (1 51) or EPA + gamma-
linolenic acid (1 8:3 n-6, GLA) (1 29). 
Sudden cardiac death and arrhythmias 
The most consistent and sound correlation between the intake of n-3 fatty 
acids and cardiovascular health benefit is their effect on sudden cardiac death 
and cardiac arrhythmias. The precise mechanism by which n-3 fatty acids exert 
their effect on arrhythmias is not completely understood, however, the current 
body of evidence centers around two main hypotheses. The first explanation is 
related to the ability of polyunsaturated fatty acids to modify the electrophysiology 
of heart muscle cells. N-3 fatty acids increase the threshold for heart muscle 
action potential and subsequent contraction through their effect on myocyte ion 
channels (both Na+ and Ca2+), and this may in part explain their ability to provide 
stability and anti-arrhythmic benefit to the heart (83, 84 ). Another possible 
mechanism is specifically the dietary modification of myocyte phospholipid fatty 
acid composition by n-3 fatty acids which replaces AA in the myocyte membrane 
and shifts the potential away from the production of series-2 eicosanoids to 
series-3 eicosanoids (1 52). This has been shown to reduce arrhythmia and 
sudden cardiac death through the reduction of series-2 eicosanoid thromboxane 
A2 (1 53) . The majority of both observational studies and intervention studies 
found a decrease in sudden death with LCn3 intake from diet (1 22, 1 25, 1 54, 
1 55) or supplementation (1 28, 1 51 ). Several studies also showed that ALA 
consumption is related to a reduced risk of sudden cardiac death (1 28, 1 32, 1 35, 
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1 36). One study reported a relative increase in sudden death based on advice to 
consume fish or fish oil capsules (1 56), however, this is an exception. 
Blood triglyceride reduction 
EPA and DHA (1 57) are consistently shown to reduce circulating 
triglyceride levels by 1 0-33% (1 58). Several mechanisms are believed to be 
involved in this reduction, including: a decrease in hepatic triglyceride synthesis 
via reduction of activity in enzymes involved in fatty acid and triglyceride 
synthesis; decreased secretion of triglyceride from the liver as VLDL; and an 
increase in peripheral lipoprotein lipase which results in an increase in 
triglyceride clearance from the blood ( 159-1 6 1 ). Fasting plasma triglyceride 
levels greatly effect the post-prandial rise in triglyceride concentration ( 1 60) and 
potential decrease with dietary n-3 fatty acid consumption, with higher basal 
triglyceride levels resulting in a greater potential reduction (1 58). Though 
triglyceride level itself has not emerged as a consistent independent risk factor 
for CVD, it has been suggested that the interdependent nature of triglyceride, 
LDL, and HDL as lipid carriers may mask the independent role of triglyceride 
levels (1 60). Increased dense LDL levels (1 62) and reduced HDL levels (1 63), 
both risk factors for CVD, are partially dependent on triglyceride levels and may 
actually prove a concurrent or secondary event to elevated triglyceride levels. 
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Cardiovascular summary 
Though results and significance vary, it is generally accepted from many 
large studies that n-3 fatty acid intake (particu larly LCn3) offers a beneficial effect 
through the reduction of specific cardiovascular health outcomes such as CVD 
mortal ity, sudden death (cardiac arrest), and myocard ial infarction (1 37). It is 
also noteworthy that although the results of studies using LCn3 or ALA are varied 
and do not lend easily to clear cut recommendations , the potential benefits of 
increased ALA and LCn3 intake outweigh the sl ight, if any, potential ly negative 
outcomes ( 1 37). 
Cancer 
At the present time, evidence supporting a beneficial role for n-3 fatty 
acids in the prevention and treatment of a variety of cancers is much stronger in 
animal models and cel l  cu lture studies than in human epidemiological stud ies 
(95). Benefit of n-3 fatty acids has been reported with human breast (1 64 ), 
colorectal ( 1 65-1 67), pancreatic (1 68, 1 69) ,  lung (1 69-1 71 ), prostate (1 72-1 74), 
and skin cancer (1 75, 1 76), however, the conclusions have not always been 
consistent and the overal l  effect of n-3 fatty acids and cancer in humans remains 
uncertain. Several plausible mechanisms for potential benefit have emerged 
from cell and animal studies, with inhibition of AA derived eicosanoids 
representing the most promising explanation of benefit ( 1 77, 1 78). AA derived 
PGE2 production has been implicated in several key pathways that promote 
prol iferation of cancer cells, growth of a capil lary support system (angiogenesis), 
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and metastasis of cancer cells to other tissues (179, 180). Other potential 
mechanisms include: inhibition of tumor proliferation through the agonism of 
PPARy, reduction of NFKB activation and TNFa expression, reduction in ras 
oncogene induction, COX-2 supression, reduction in cytochrome p450 
aromatase activity resulting in reduced estrogen production, and upregulation of 
antioxidant enzyme systems contributing to the amelioration of reactive oxygen 
species as potential pro- tumorigenic mutagens ( 178, 181 ). One of the 
potential reasons for contradictory findings between animals and humans may be 
that the doses given in animal studies looking at the association between n-3 
fatty acids and cancer exaggerate the likely effects in humans (178). This 
problem emphasizes the motivation of the current study to determine "human 
equivalent" n-3 fatty acid doses for animals that can offer better predictive value 
to anticipated effects in human trials. 
EPA intake has also been implicated as a treatment option for cancer 
related cachexia (182). Though initial findings looked as though EPA may 
improve appetite, weight status, and possibly even survival (183, 184 ); larger 
comparative trials have not shown any significant improvements ( 1 85-1 87) with 
administration of EPA. 
Inflammation 
Several disease states that have an underlying inflammatory component 
may benefit from the potential anti-inflammatory action of n-3 fatty acids. These 
include: cardiovascular disease (188), rheumatoid arthritis (189), air-way 
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inflammation (asthma), systemic lupus erythematosis, and inflammatory bowel 
disease (190). Eicosanoids derived from AA act as stimulants of inflammation 
and systemic immune response through cyclooxygenase and lipoxygenase 
products, particularly, PGE2 and L T84 (191). EPA competes as a substrate for 
COX and LOX and the resultant 3-series prostaglandins and 5-series 
leukotrienes are less inflammatory than the AA derived products. In addition to 
modifying eicosanoid production, fish oil supplementation has been shown to 
suppress the expression of IL-1� (192-195), TNF -a (194, 195), and IL-6 (194), 
with ALA supplementation also decreasing IL·1� (195), TNF-a (195), and IL-6 
expression (196). Habitual intake of EPA + DHA were also shown to be inversely 
associated with the expression of plasma TNF receptors (8). Though the ability 
of n-3 fatty acids to attenuate the inflammatory and immune response is 
desirable in these disease states, it should also be noted that a reduction in 
immune response elicited by n-3 intake may be an unwanted outcome in those 
individuals fighting an infectious disease (197), and particularly those who are 
already immunocompromised ( ex: the elderly). 
Diabetes 
N-3 fatty acids do not appear to offer significant beneficial effects for the 
treatment of diabetes mellitus. A recent report investigating the effect of n-3 fatty 
acids on several cardiovascular disease risk factors concluded that n-3 fatty 
acids had no significant effect on hemoglobin A1 C levels, and had no consistent 
effect on fasting blood sugar or fasting insulin levels (158). While impaired 
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glycemic control has been reported in some studies with high supplemental n-3 
doses (198, 199), n-3 fatty acids are generally found to have no significant 
effects on glycemic control (200-206), including an18 study meta-analysis which 
found no significant effects of n-3 fatty acid supplementation on fasting glucose 
or hemoglobin A1C levels in Type 2 diabetics (207). 
Psychological disorders 
The high levels of DHA found in brain tissue coupled with the discovery 
that n-3 fatty acid status in various tissues (mainly RBC PL) is decreased in 
schizophrenia (208), adult (209) & childhood (210) attention-deficit/hyperactivity 
disorder, and depression (211, 212), has stimulated research looking at possible 
connections between n-3 fatty acid intake and several psychological disorders. 
Supplementation has been found to improve objective measures of unipolar 
depressive disorder (213), dark adaptation in dyslexia (214), and has been 
reported to lengthen the remission of symptoms in patients with bi-polar 
depression (215). In general, the majority of studies in schizophrenics have also 
shown a beneficial effect from EPA supplementation (2 16) when compared to 
placebo controls (217-219) with few exceptions (220). N-3 fatty acids have also 
been suggested for attention-deficit I hyperactivity disorder and other childhood 
developmental disorders, though two recent placebo-controlled trials 
supplementing DHA did not report an improvement in ADHD symptoms (221, 
222), with another study reporting no improvement in physical aggression in 
children who were supplemented with EPA + DHA (223). An interesting 
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hypothesis put forth by Hibbeln et al., suggests that mortality from coronary heart 
disease and depression increases across several countries as n-3 fatty acid 
intake declines (224, 225). This further potentiates the role of n-3 fatty acids in 
psychological phenomena and this area of research calls for large scale definitive 
trials for conclusive answers. 
Pre and postnatal development 
Increased understanding of the important role that n-3 fatty acids 
(particularly DHA) play in brain and retina development has stimulated many 
studies examining the effect of n-3 supplementation during different stages of 
development, for example, the impact of maternal diet on prenatal development 
and the mode of feeding (breast milk, standard formula, or formula with added 
long chain PUFA) on postnatal development in term and pre-term infants. These 
studies were recently reviewed by an expert committee workshop of the Child 
Health Foundation (226) producing recommendations for maternal and infant n-3 
intake based on available evidence of potential benefits. Thus far, it is generally 
considered unnecessary for pregnant women to supplement n-3 fatty acids (226), 
though it is encouraged that they include DHA rich foods in their diet. Attention to 
n-3 fatty acid status may prove particularly beneficial in specific subgroups of 
pregnant women, such as vegetarian women and women who are pregnant 
subsequent to a first birth (based on the finding that DHA status is best in the first 
child and maternal stores of DHA decline in subsequent pregnancies (59)). After 
birth, it is highly encouraged that infants are breast fed (226). It is also 
33 
encouraged that infants who are not breast fed receive formula supplemented 
with AA and DHA (226, 227), with higher concentrations of AA and DHA for 
preterm infants (226), based on a greater potential for benefit of supplementation 
in preterm infants (53, 64, 228, 229). 
Safety of fish consumption 
Parallel to increasing public and scientific interest in n-3 fatty acid benefits, 
regulatory agencies such as the Environmental Protection Agency and the FDA 
have expressed concern touting the link between fish consumption and 
methylmercury exposure. As a by-product of industrial emissions and 
volcanoes, mercury finds it way into water bodies through environmental 
precipitation (230). Predatory fish become the main repository of mercury 
accumulation through successive concentration at each level of the food chain 
(231 ). Nervous system tissue is the most vulnerable to mercury exposure, 
particularly fetal neural tissue (232). Research findings have been contradictory 
as to the impact of mercury from fish consumption on possible heart related 
benefits. Guallar et al. (233), found an association between mercury level in 
toenail clippings and risk of myocardial infarction incidence in men, while 
Yoshizawa et al. (234), did not find an association between mercury levels and 
incidence of coronary heart disease. Current advisories suggest that women 
who are planning a pregnancy or are currently pregnant or lactating and young 
children should avoid four types of fish with the highest mercury content: tilefish, 
swordfish, king mackerel, and shark (235), while other demographic groups 
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should balance fish intake between those with high and low mercury content 
(Table 1 -4). It is likely that potential harm from mercury exposure based on 
current fish consumption patterns is outweighed by the potential benefits, 
particularly for those who are at risk of coronary heart disease (9, 230, 231). An 
alternative source of n-3 fatty acids is refined fish oil supplements, which have 
very low mercury content (231 ). More research is needed to fully understand the 
potential risk of mercury exposure and possible counterproductive impact on 
cardiovascular benefits provided by fish consumption. 
1 .3 Animal model research and omega-3 fatty acid supplementation 
Animal models in research 
According to the National Research Council (236), an animal model is "a 
living organism in which normative biology or behavior can be studied, or in 
which a spontaneous or induced pathological process can be investigated, and in 
which the phenomenon in one or more respects resembles the same 
phenomenon in humans or other species of animal (as modified in (237))." 
Several animal models are currently used in biological research, including: mice, 
rats, hamsters, rabbits, guinea pigs, monkeys, dogs, and swine. Animal models 
are not intended to perfectly mimic human function (238-240), but to provide a 
Table 1 -4  
FDA/ EPA recommendations for fish intake 1 
Fish to avoid 
Shark 
Swordfish 
King Mackerel 
Tilefish 
(a .k.a. Golden bass, 
Golden snapper) 
Fish to consume in 
limited quantities 
(up to 6 ounces/wk.) 
Canned Albacore 
"White" Tuna 
Fish lowest in methyl mercury: 
Catfish (farmed), King Crab, 
Flounder (summer), Scallops, 
Trout (farmed), Salmon (wild 
Pacific), Shrimp, Tilapia, Sardines 
Fish to consume in 
limited quantities 
(up to 1 2  ounces/wk.) 
Canned Light Tuna 
Sea Bass 
Gulf Coast Oysters 
Marlin 
Halibut 
Pike 
Walleye 
White Croaker 
Largemouth Bass 
Mahi Mahi 
Blue Mussel 
Cod 
Eastern Oyster 
Channel Catfish (wild ) 
Great Lakes Salmon 
Gulf Coast Blue Crab 
Lake Whitefish 
Pollack 
1 Recommendations are for women who are/ may become pregnant, are nursing, and small 
children. 
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"surrogate" (241 , 242) that is often better control led and better able to answer 
narrow research questions than could be determined from highly variable human 
activity (243) .  Specimens from inbred animal strains (ex: mice) used in research 
are almost genetically identical (244 ), thus eliminating much of the inherent 
genetic variabil ity found in human studies performed on mixed populations . The 
choice of a particular animal model depends on the research question that is 
being investigated and how closely a species matches humans in the mechanism 
of inquiry (243) .  Selection of the appropriate animal model is also based on 
criteria such as: availabil ity of a particular model to many investigators , handling 
abil ity of a particle animal , multiparous reproduction, adequate yield of 
specimens necessary for assessment (245), and precedence of research using a 
particu lar model in the field of study (246). In add ition , proliferation of genomic 
research in recent years has increased the selection of models based on known 
genetic homology between humans and animals (243). 
Advantages of the murine model 
There are several advantages to using the mouse model in nutrition 
research . Mice are generally inexpensive to purchase and feed (though cost 
depends on genetic strain and diet selection) .  Small size allows for caging of 
multiple animals in groups and requires less space than other models (24 7) .  
Mice reproduce qu ickly (247) and are multiparous (246), which has contributed to 
the formation of several inbred strains for purchase , which are nearly 1 00% 
homozygous (246). The wide use of rodents over the last century has produced 
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a plethora of publication precedence, making the mouse model more trusted than 
newer, less documented models. In recent years, both the mouse (248) and 
human genome (249) have been categorized, revealing a relative 70-90% 
genetic homology between mice and humans (250). This has made mice a 
particularly useful model for studying human biological processes that have been 
conserved between the two species (244, 251 ). Specifically, mice are useful for 
n-3 fatty acid research because the same fatty acids are essential in mice and 
humans. Mice also metabolize fats through the same pathway and house the 
same enzymatic machinery for polyunsaturated fat processing as humans (66). 
Disadvantages of the murine model 
Few disadvantages exist in the use of the mouse for nutrition research. In 
reference to their use in lipid metabolism, it has been reported that �5 and �6 
desaturase activity in rodents is greater than the rate of human desaturases 
(252 , 253). This detail is sometimes cited in an attempt to discredit the use of the 
mouse model as a surrogate for human fatty acid metabolism. However, 
expectation and quantification of this rate difference should not hinder 
reasonable extrapolation to humans from murine data. It has also been shown 
that DHA levels in several human tissues are reduced compared to rodents 
(254), further suggesting a possible difference in conversion capacity. Another 
possible disadvantage is that mice are not considered a high fidelity model for 
certain human diseases such as the development of atherosclerosis. This is due 
to the difference in predominant cholesterol carrying lipoproteins between 
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rodents and humans (255). This is also based on the resistance of rodents to 
dietary fat induced atherosclerosis (255). 
Design improvements for murine model research with omega-3 fatty acids 
Choice of control/background diet 
We have observed that one of the significant methodological problems 
with rodent studies supplementing n-3 fatty acids is the use of a control 
(background) diet that is not representative of typical human consumption 
patterns. When supplemented groups are compared to control diets that are 
devoid of long chain polyunsaturated fatty acids EPA, DHA, and AA, the results 
will likely demonstrate exaggerated increases of n-3 fatty acids in a variety of 
tissues due to the lack of metabolic constraints enforced by the presence of other 
LCn3 and AA in the control diet. We believe the solution to this problem (as 
detailed below and in Chapters 2 and 3) involves the calculated addition of all 
polyunsaturated fatty acids in a manner that is representative of their relative 
proportion in the typical (Western) human diet. It has been suggested that, " . . .  if 
the (experimental) design inadequately represents the 'normal' life conditions of 
the target species, inaccurate conclusions may be drawn, regardless of the value 
of the model itself' (240). When applied to nutrition studies, this statement 
highlights _the need for the diet design of the model species (in this case, mice) to 
model the diet of the target species (humans) in order for accurate conclusions to 
be drawn from the analysis. 
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Relevant dosing 
A recent survey of general studies using supplemental n-3 fatty acids in 
rodents shows that current supplemental doses are not representative of 
reasonable expected human consumption (Table 1-5). Standardization of 
supplemental n-3 fatty acid doses in mice that represent a "human equivalent 
dose" is necessary if animal studies are to have true predictive value for humans. 
The precedent for change, in part, comes from observations in toxicological 
studies utilizing, "physiologically based pharmacokinetic" (PBPK) modeling (256) 
(also called "biologically based dose-response (BBDR) (257, 258)). 
Physiologically based modeling is meant to reduce extrapolation of dosages 
between two species to a mathematical model (257) that is based on the 
metabolism of the given substance in each species. Building on this concept, it is 
feasible that a mathematical model describing the expected influence of dietary 
n-3 fatty acids on the same endpoints in different species can be derived. Below, 
we introduce a simple mathematical model for the standardization of 
supplementation that allows for direct comparison of biological endpoints 
between rodents and humans. We have put forth a rudimentary, easy to use, 
estimation of this model with the knowledge that a more precise estimation in the 
future may be necessary. 
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TABLE 1-5 
Review of supplemental doses of omega-3 fatty acids 
given in recent rodent studies. 
Study ALA EPA DHA HED1 
----- energy % ------- grams 
ALA EPA 
Cognault et al . (259) 16.8 37.3 
Massiera et al. (260) 5.7 12.7 
Miyazawa et al. (261 ) 3.6 8 
Mori et al. (262) 23.2 51.6 
Morise et al. (263) 13.8 30.7 
Takemura et al.(264) 11.4 25.3 
Saito et al. (265) 8.2 7.8 7.6 18.2 17.3 
Oarada et al .(266) 16.1 5.1 3.3 35.8 11.3 
Ide, et al.(111) 16.7 2.9 8.6 37.1 6.4 
Kim et al.(267) 10.6 1.2 6.2 23.5 2.7 
Takahashi et al. (268) 23.9 3.8 12.4 53.1 8.4 
Maison et al.(269) 6.9 4.0 15.3 
10.2 7.5 22.7 
Choi-Kwon et al. (270) 3.5 2.3 7.8 
Joshi et al. (271) 2.4 1.7 5.3 
Akisu et al. (272) 3.4 2.3 7.6 
Oarada et al. (273) 5.4 5.4 12 
Watanabe et al. (274) 5.4 5.4 12 
Wang et al . (275) 9.7 
Cha et al. (276) 2.6 
6.5 
1 Human Equivalent Dose based on energy% of a 2000 calorie diet. 
DHA 
16.9 
7.3 
19.1 
13.8 
27.6 
8.9 
16.7 
5.1 
3.7 
5.1 
12 
12 
21.6 
5.8 
14.4 
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Significance of omega-3 fatty acid form 
The media as well as medical professionals often propagate a blurred 
distinction between the expected attributes of ALA and those of LCn3, EPA, and 
DHA. N-3 fatty acids are lumped together as a unified entity and even prescribed 
almost interchangeably. The benefits reviewed above show that there is a much 
greater research base supporting a beneficial effect of LCn3 intake than for ALA. 
We have attempted to further clarify this difference in the context of an 
experimental design with background long chain fatty acids and supplemental 
doses that better represent human intake. This comparison is necessary to 
demonstrate the individual effects of ALA and LCn3 on tissue accumulation, 
conversion to metabolites, and influence on pertinent endpoints. 
1.4 Summary 
Jon R. Held summarizes the purpose of animal model research as follows, 
"The whole history of biomedical research tells us the countless benefits to 
humans obtainable by asking the right questions of the right animal model (237)." 
We believe that the validity of n-3 fatty acid research in the rodent model extends 
only as far as the design of the experiment. Supplemental studies in animals are 
by nature wrought with many complex associations between the diet of man and 
the murine diet. In order for the "right question" and the "right animal model" to 
yield meaningful answers, methodological changes are necessary in the way that 
n-3 fatty acid research in rodents is performed. 
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1.5 Research Objecti\fe 
1. To develop a hypothetical diet model for the study of n-3 fatty acids in rodents 
that allows for better comparison of mouse and human endpoints. 
2. To clarify the relative impact of n-3 fatty acid form and amount on measurable 
biological endpoints. 
Specific aims 
1. To test the use of energy% as a model for the addition of fatty acids 
to rodent diets with comparison to archival human data. 
2. To compare the effect of ALA and EPA on plasma and erythrocyte 
phospholipid fatty acid content when these fatty acids are given at 
equivalent supplemental levels in the context of a background diet ' 
that contains long chain PUFA (n-3 and n-6). 
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2 RELEVA1NT DOSING FOR ANIMAL MODELS: A SCALING APPROACH 
2.1 Introduction 
The design and implementation of dietary research with animal models 
requires thoughtful examination of interspecies variation. In order for data 
achieved from these studies to be used for meaningful extrapolation, levels of 
supplemental nutrients must be a reasonable representation of what can be 
consumed by humans. Are we considering these interspecies differences when 
we design dietary studies, or has the use of animal models become so 
widespread that we have overlooked the need for calculated extrapolation? If 
dietary animal studies are to have true predictive value for anticipated results in 
humans, we must stretch beyond the scope of nutrition and adopt an integrative 
perception of animal modeling that considers the discoveries of parallel 
disciplines. 
A natural starting point for this integration is the study of basal metabolic 
rate and its relationship to bodyweight in mammals. The analysis of metabolic 
rate has been one of the most prevalent examples of interspecies comparison 
over the last century. In 1932, Max Kleiber, well known pioneer in the field of 
animal energetics, discovered that over a large range of animal size (from rats to 
oxen) linear regression of the logs of weight and metabolic rate produced a ¾ 
exponent (277-279) based on the following equation: 
Y= axb 
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Where Y is metabolic rate in kcal, x is bodyweight in kilograms, a is the 
proportionality constant, and b is the scaling exponent and the slope of the 
regression line depictiing this relationship (280). Kleiber's discovery differed from 
a long held reliance on ½, which was the anticipated exponent from geometric 
evaluation of surface area and volume alone (281, 282). Shortly after Kleiber's 
discovery, Brody et al. (283), added more mammals to Kleiber's analysis and 
deduced the same scalin�i exponent, ¾ , for animals ranging in size from a 
mouse to an elephant, yielding the often cited "mouse to elephant curve". 
However, ¾ scaling was not without its dissenters. For a variety of reasons, 
several researchers have held firm to ½ scaling (284-288). 
In the past decade, there have been many interesting attempts to expand 
our understanding of why Kleiber's ¾ scaling may exist in nature. West et al. 
(289-293), have presented several papers detailing the physical constraints of 
"hierarchical branching networks" within organisms that dictate a ¼  (or multiple 
thereof, including ¾ ) scaling between many biological variables and bodyweight. 
This theory was tested in mammalian species, birds, plants, unicellular 
organisms, sub-cellular fractions (mitochondria), and enzymes; and the 
conclusion was made that metabolism is confined to the dimensions of circulation 
and circulation is dictated by the same fractal geometric confines from one 
species to another. Other views supporting ¾ scaling include: 
• A "multiple cause model of allometry"(294) that takes into account every 
ATP utilizing and generating construct within the biological system that 
contributes to metabolic rate ( Ex: organ size, hormonal state, 
temperature, pressure, ecological parameters, etc .. . ) (295-297) 
• An ecological perspective (298), in which the relationship between 
metabolic rate and body size is examined based on the influence of 
geographical region of evolution. 
• The use of geographical food productivity and abundance (299) to 
determine the influence of food availability in different regions on 
metabolic rate. 
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Figure 2-1 summarizes some of the major theories used to explain the scaling of 
metabolic rate between animal species and how this fits into the scheme of 
dietary intake. 
Three-quarter power scaling in nature is an example of how comparative 
physiology can be used to guide the design of animal model research, and 
particularly, the dosing of supplemental components in dietary studies using 
animal models. Currently, no clear standard of practice drives the derivation of 
nutrient doses in dietary animal model research. Doses are conceived based on 
various methods such as: comparison of weights between animals and humans, 
duplication of doses from similar studies, and in some cases, dosing values 
derived merely to maximize the potential for positive results without conscious 
interspecies evaluation. Therefore, we set out to establish a mathematical model 
that could be used as a guideline for choosing levels of n-3 PUFA in rodent diets 
that would facilitate reasonable extrapolation to humans. In order to be useful, 
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this model should : linearize the relationship between human and rodent data; be 
applicable to the general range of n-3 fatty acid studies; be tested on the basis of 
its ability to yield similar biological effects in animal models and humans; and 
most importantly, be simple to use. 
Because supplemental components in dietary studies either have caloric 
value or are dependent on the difference in metabolic rate between species, we 
suggest that a model based on consideration of daily energy consumption in 
rodents and humans may offer a means of dose standardization. The 
comparison of daily energy consumption between two organisms (ex: between 
mouse and man) should be an indirect picture of the differences in digestion, 
absorption, energy expended in activity, metabolic rate, and nutrient needs 
between the two organisms, particularly if they are in energy balance with no net 
weight gain or loss. Supplementation based on energy consumption is 
supported by Rucker et al., who suggest, " . . .  when making interspecies 
comparisons from a nutrition perspective, the strongest case is made when a 
measure of metabolic body size or food intake, rather than bodyweight is used to 
extrapolate the dosages required for a given response" (300). Rucker also 
points to the inherent similarity between caloric needs and water-soluble vitamin 
requirements in homeotherms (301 ). Since vitamin requirements and caloric 
intake are under similar biological controls, a "human equivalent dose" model 
should be able to predict both the supplementation levels in animals that would 
match human intake and should also be able to predict human vitamin 
requirements from known animal vitamin requirements. Vitamin and mineral 
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intake recommendations have been made for both rodents and humans, and 
loosely represent perceived requirements. These known recommendations offer 
a means to test the predictability of scaling theories between rodents and 
humans. 
2.2 Methods 
Several published works have established the nutrient needs of humans 
(302-306) and mice (307, 308). We used this information as a means to test the 
ability of the following hypothetical models to predict the Dietary Reference 
Intakes for humans from mouse requirements when used as a mathematical 
conversion factor: 
A. Bodyweight (in kilograms) 
B. [Bodyweight (Kg)]" ¾ 
C. Daily energy consumption (% energy). 
Derivation of the above scaling factors for mouse to human comparison is 
detailed in Table 2-1. Briefly, human weight (Kg), [weight (Kg)] " ¾, and daily 
calorie intake was divided by the same data for an average mature mouse to 
produce a conversion factor based on each hypothetical scaling model (A-C). 
Established murine vitamin and mineral intake recommendations were multiplied · 
by each conversion factor and compared to the Dietary Reference Intakes of 
each nutrient for humans. The levels of linoleic acid (LA) and a-linolenic (ALA) 
acid present in the typical daily intake of rodent diet were also used to test the 
TABLE 2-1 
Derivation of conversion factors 
Bodyweight (Kg) 
[Bodyweight (Kg)]A ¾ 
Daily caloric intake 
Mouse1 
0.025 
0.063 
1 4.4 
Human 
70 
24.2 
2000 
Human 
Mouse 
2800 
384.8 
1 38.89 
1 Based on a C57BU6J adult mouse, consuming 4gms/day AIN93M diet (307). 
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predictive value of each factor to estimate human adequate intake (Al) of LA and 
ALA. 
2.3 Results 
Table 2-2 details the use of each conversion factor to estimate the Dietary 
Reference Intakes for vitamins, minerals, and fatty acids (LA and ALA) from 
known mouse nutrient requirements (307). In comparison to the factors based on 
weight (Kg) and [weight (Kg)] ¾, the factor for energy% best predicted the DRls 
for 1 2  of 1 2  vitamins and 9 of 1 2  minerals. The minerals in which energy% was 
not the best scaling predictor were sodium, potassium, and chloride. The 
estimations based on energy% were also the best predictor for the Al of LA and 
ALA in humans. 
Nutrient 
VITAMINS 
Thiamin 
Riboflavin 
Vitamin 86 
Niacin 
Folate 
Biotin 
Vitamin E 
Vitamin D 
Vitamin A 
Vitamin K 
Vitamin 812 
Pantothenate 
MINERALS 
Calcium 
Phosphorus 
Potassium 
Sodium 
Chloride 
Magnesium 
Chromium 
Copper 
Iodine 
Iron 
Selenium 
Zinc 
TABLE 2-2 
Scaling of daily nutrient requirements for mice to human Dietary Reference Intakes 1•2 
Scaling Factors 
Daily Requirement Body Weight (Kg)3 [Body weight (Kg)]A·75 3 °lo Energy4 RDA/Al5 
0.0214 59.9 8.2 3.0 1 .2 mg 
0.024 67.2 9.2 3.3 1 .3 mg 
0.0233 65.2 9.0 3.2 1 .3 mg 
0. 1 2  336 46 1 7  1 6  mg 
8 22,400 3079 1 1 1 1  400 µg 
0.8 2240 308 1 1 1  30 µ9 6 0.201 563 77 28 1 5  mg 
3 8400 1 155 417  5 µg 
4.8 13440 1 847 667 900 J.!9
7 
3 8400 1 1 55 417  120 µg 
0. 1 280 38 14  2.4 µg 
0.0586 164 23 8 5 mg 
1 9.99 55972 7695 2776 1000 mg 
7.98 22344 3072 1 108 700 mg 
14.40 40310 5542 2000 4700 mg 
4.1 1 1 1 505 1 582 571 1 500 mg 
6.29 17614 2421 874 2300 mg 
2.026 5673 780 281 400 mg 
8 22,400 3079 1 1 1 1  35 µg 
24.2 67, 620 9,296 3,354 900 µg 
0.83 2,325 320 1 1 5 1 50 µg 
0. 14  392 54 1 9  8 mg 
0.6 1 ,680 231 83 55 µg 
0. 1 2  337 46 1 7  1 1  mg 
01 
0 
Nutrient 
FATTY ACIDS 
a-linolenic acid 
Linoleic acid 
Daily Requirement 
0.01 1 
0.086 
Soutte: 4*02-309, 308) • 
Body Weight (Kg)3 
30.8 
242 
TABLE 2-2 
Continued 
Scaling Factors 
[Body weight (Kg)JA·
75 3 
4.2 
33 
2 Based on 4 grams (average daily intake) of AIN93M purified rodent diet. 
3 Based on a 70 Kg human and 25 gram mouse. 
• Based on 14.4 calories (average daily mouse intake based on 4 grams AIN93M diet) (307) and 2000 calorie human diet. 
5 Based on 30 year old male 
6 a-tocopherol 
7 µg retinol 
% Energy" 
1 .6 
12  
RDA/Al5 
1 .6 
1 5  
g m  (302) 
gm (302) 
01 
.....a.. 
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2.4 Discussion 
Selection of appropriate doses for supplemented nutrients in animal 
studies is a common challenge faced by nutrition researchers. Extrapolation of 
animal model data to humans necessitates the use of supplemental doses that 
are both biologically relevant and reasonable for human intake. However, there 
are currently no standards of practice guiding researchers in the addition of 
dietary components in animal studies other than precedent. In the words of 
Yates, et al., "We need principles of data extrapolation to justify transforming 
data from one system (species) into data about another, different system. We 
need to know what scaling principles can guide the designs of our experimental 
protocols" (309). The tentative search for a "human equivalent dose" lies at a 
complex intersection of diverse fields of insight, from comparative physiology and 
evolutionary biology, to bioenergetics and theoretical mathematics. It is from this 
intersection, with consideration and input from this diversity, that we present a 
simplified approach to relevant nutrient dosing in animal studies. 
Dietary recommendations for animals are formulated to meet daily dietary 
requirements and to avoid un-utilized excesses. Diets are formulated to provide 
levels of nutrients to support growth, reproduction, lactation and maintain health. 
As such, micronutrient and amino acid compositions of these diets are well 
characterized and defined. Any deviation from recommended nutrient levels 
requires appropriate justification. This is not the ca�e with dietary fats. While the 
lipid content has been standardized in rodent diets to provide either corn oil at 
5% (w/w) (eg., AIN76A) (239) or soybean oil at 4% or 7% (w/w) (AIN93M or 
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AIN93G, respectively) (307), l iberties are taken with fatty acid compositions that 
appear to lack reasonable justification; such as replacing all the corn oil in a diet 
with pure coconut oil to simulate a high saturated fat diet. This is particularly true 
with studies evaluating the dietary effects of n-3 PUFA. For example, a random 
search of recent l iterature reveals the large variation of levels of n-3 PUFA that 
are provided in rodent diets, primarily at the expense of corn oil .  These intakes, 
in the form of ALA, EPA and/or DHA, ranged from 2.6-40 energy% (Table 1-5). 
This is in comparison with typical human intakes of 0.5 and <0.09 energy% for 
ALA and EPA+DHA, respectively (6-8). Will these levels produce biological ly 
relevant data if they are incompatible with human consumption? While the uses 
of PUFA are tailored for the objectives of each study, it seems reasonable that 
guidelines framing appropriate levels are needed, with justification warranted 
when unusual deviations from these guidelines occur. 
Recently, Rucker and Storm (300) discussed approaches that have been 
used to extrapolate nutrient intakes to that of humans. Their paper plotted the 
log10  of body weight (Kg) against the 10910 of nutrient intake (mg) in 5 different 
species , including humans. In doing so, metabolic differences of species were 
taken into account and the relationship of nutrient intake versus body weight for 
each of the species became linear. Similarly, we are interested in establishing a 
mathematical model that provides the foundation for allometric scaling of dietary 
PUFA intake between rodent and humans. 
Evaluation of several different conversion factors lends credence to a 
dosing model based on energy% as an appropriate factor for dietary components 
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between species. Though energy % is not a precise match for every nutrient, 
overall, it produces a better match to human nutrient recommendations than 
factors based on bodyweight (Kg) or [bodyweight]A ¾. Precise mathematical 
modeling of the relationship between an animal's nutrient needs and the DRls is 
beyond the scope of this paper, however, we believe that allometric scaling 
based on an energy % factor produces a better model for derivation of a "human 
equivalent dose" than other methods currently employed. In order to further test 
the predictive value of em�rgyo/o dosing in mice and humans, we have also tested 
this hypothesis in the form of a pharmacodynamic experiment with omega-3 fatty 
acid supplementation and hematological endpoints in both species (Chapter 3). 
2.5 Conclusions 
We suggest that adding dietary components on the basis of energy % is 
an efficient way to narrow the gap between human intake and rodent intake. It is 
our hope that the presentation of this model will stimulate necessary thought and 
debate concerning the supplemental levels that are currently used in dietary 
studies. Ideally, dietary studies of the future will represent a true integration of 
theoretical comparative physiology and nutrition science. The issues raised here 
are only the beginning. 
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3 HUMAN EQUIVALENT DOSE MODELING FOR OMEGA-3 FATTY ACID 
SUPPLEMENTATION IN C57BU6J MICE 
3.1 Abstract 
The rodent model is often used to study the impact of dietary n-3 fatty 
acids on a variety of biological endpoints, and the results of these studies have 
been used to explain anticipated effects of n-3 fatty acid intake in humans. 
However, supplemental levels of n-3 fatty acids that are commonly used in 
rodent studies do not represent reasonable human intake, by comparison. 
Currently there is no standard method for the addition of n-3 fatty acids to rodent 
diets. We tested a mathematical model for dosing supplemental levels of a­
linolenic acid (ALA) and eicosapentaenoic acid (EPA) to rodent diets on the basis 
of energy%. C57BI/6J mice were fed a background diet that modeled typical 
Western intake in both macronutrient and fatty acid composition. Three levels of 
ALA and EPA (0.3, 0.8, and 1.4 energy%) were supplemented to either a normal­
ALA control diet (0.6 energy% ALA) or a high-ALA control diet (1.2 energy% 
ALA). Plasma and erythrocyte phospholipid fatty acid changes were determined 
and compared to archival human n-3 fatty acid supplementation studies reporting 
the same tissue endpoints. In mice, supplemental EPA had a greater effect than 
supplemental ALA on both plasma and erythrocyte phospholipid EPA. 
Docosahexaenoic acid (DHA) levels in mice were only minimally changed by 
either ALA or EPA supplementation. Use of the high- ALA control diet resulted in 
attenuated phospholipid fatty acid changes in both tissues compared to the 
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normal-ALA control diet for both supplemented fatty acids. At each 
supplemented dose of ALA or EPA, changes in murine plasma or erythrocyte 
phospholipid EPA exceeded changes observed in the same human tissues by 
2-4 fold when compared to equivalent human supplemental doses in energy%. 
Tissue changes observed using the high-ALA control d iet better modeled the 
results observed in humans at the same supplemental energy% for both ALA and 
EPA in plasma and erythrocyte phospholipids. This is the first study to use 
pharmacodynamic modeling to compare the effect of supplemental n-3 doses on 
mouse and human endpoints. The addition of n-3 fatty acids to rodent diets on 
the basis of energy% represents a reasonable improvement to current dosing 
strategies. This data is useful, both as a guideline for n-3 fatty acid dosing in 
rodent studies and as a reference point for future calculated refinements in 
dosing. 
3.2 Introduction 
Recently, we suggested the use of energy% as a model for lipid dosing in 
dietary research using the rodent model. Comparison of rodent nutrient 
requirements and human intake recommendations reveal that an energy% factor 
has better predictive value for estimating human requirements from animal 
requirements than either weight (Kg) or (weight (Kg))¾ (Chapter 2). The current 
study is designed to further test the applicability of an energy% model based on 
the comparison of common biological endpoints in mice and humans. Energy% 
is used as a tool to formulate a "Western" background diet as well as 
supplemental doses of two common n-3 fatty acids: a-linolenic acid (18:3n-3, 
ALA) and eicosapentaenoic acid (20:5n-3, EPA). By capturing corresponding 
mouse and human endpoints and standardizing the supplementation values on 
the basis of energy%, we offer a touchstone for anticipated effects at these 
doses and a template for further investigation in the quest for a "human 
equivalent dose". 
3.3 Materials and Methods 
Animals 
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Male, C57BU6J mice (The Jackson Laboratory, Bar Harbor, ME) were 
used in the following experiments. All mice were received at 35-42 days of age 
and housed 5 per cage. Animals were given free access to food and water and 
were maintained in a climate controlled facility with programmed light and dark 
cycle. Mice were checked daily for health and general well-being. An Animal 
Use Protocol was filed and approved by the University of Tennessee Institutional 
Animal Care and Use Committee ( IACUC). 
Diets 
All diets were prepared by Research Diets (New Brunswick, NJ) (Tables 
3-1 and 3-2). The fatty acid ethyl esters were purchased from Nu-Chek Prep 
(Elysian, MN). Aliquots of diet were bagged separately and stored at -20° C 
Diet Component 
Casein 
L-Cystine 
Cornstarch 
Maltodextrin 1 0  
Sucrose 
Cellulose 
Cocoa Butter 
Linseed Oil 
Palm Oil 
Safflower Oil 
Sunflower, Trisun1 
1 8:3 n-3 ethyl ester2 
-20:4 n-6 ethyl ester2 • 
20:5 n-3 ethyl ester2 
22:6 n-3 ethyl ester2 
Mineral Mix S1 00263 
Dicalcium Phosphate 
Calcium Carbonate 
Potassium Citrate 
Vitamin Mix V1 3401 4 
Chotine Bitartrate 
a -Vitamin E Acetate5 
Tertiary-butyl hydroquinone 
\.. 
\ 
TABLE 3-1 
Diet Composition - High ALA study 
Control ALA-1 ALA-2 ALA-3 EPA-1 EPA-2 EPA-3 
---------------- g/kg -----------------
230 230 
3.4 3.4 
266 264 
86 86 
1 1 5  1 1 5  
57 57 
43 43 
5.2 5.2 
60 60 
33 33 
31 31 
3. 18  4.72 
0.40 0.40 
0. 17  0. 17  
0.29 0.29 
1 1 .5 1 1 .5 
15  15 
6.3 6.3 
19  19  
1 1 .5 1 1 .5 
2.3 2.3 
0 . 15 0 . 15 
0.03 0.03 
231 
3.4 
259 
86 
1 15 
57 
43 
5.2 
60 
33 
31 
7. 16  
0.40 
0. 1 7  
0.29 
1 1 .5 
15  
6.3 
19  
1 1 .5 
2.3 
0 . 15  
0.03 
232 
3.4 
253 
86 
1 1 5  
57 
43 
5.2 
60 
33 
31 
1 0.43 
0.40 
0. 1 7  
0.29 
1 1 .5 
1 5  
6.3 
19 
1 1 .5 
2.3 
0. 1 5  
0.03 
230 
34 
264 
86 
1 1 5 
57 
43 
5.2 
60 
33 
31 
3. 1 9  
0.40 
1 .72 
0.29 
1 1 .5 
1 5  
6.3 
19  
1 1 .5 
2.3 
0. 1 5  
0.03 
231 
3.4 
259 
86 
1 1 5 
57 
43 
5.2 
60 
33 
31 
3.20 
0 .40 
4.25 
0.29 
1 1 .5 
1 5  
6.3 
1 9  
1 1 .5 
2.3 
0 . 15  
0.03 
232 
3.4 
253 
86 
1 1 5 
57 
43 
5.2 
60 
33 
31 
3.21 
0.40 
7. 18  
0.29 
1 1 .5 
1 5  
6.3 
19  
1 1 .5 
2.3 
0 . 15  
0.03 
1 High-Oleic acid sunflower oil, Humko Oil Products (Humboldt, mi :. , . 
CJ1 
CX) 
2 1 8:3 n-3, 20:4 n-6, 20:5 n-3, and 22:6 n-3 ethyl esters supplied by Nu-Chek Prep (Elysian, MN). 
3 Components per Kg Mineral Mix: NaCl, 259 g; magnesium oxide, 41 .9 g, MgSO4 • 7 H2O, 257.6 g ;  chromium potassium sulfate ·12 H2O, 1 .925 g; cupric carbonate, 1 .05 g ;  sodium 
fluoride, 0.2 g; potassium iodate, 0.035 g; ferric citrate, 2 1 .0 g; manganous carbonate, 12.25 g; ammonium molybdate, 0.3 g; sodium selenite, 0.035 g; zinc carbonate, 5.6 g; sucrose, 
399. 1 05 g (Research Diets, New Brunswick, NJ). 
4 Components per Kg Vitamin Mix: vitamin A palmitate (500,000 IU/gm), 0.8 g; cholecalciferol (1 00,000 IU/gm), 1 .0 g; menadione sodium bisulfite, 0.08 g;  biotin (1 .0%), 2.0 g; 
cyanocobalamin (0. 1 %), 1 .0 g; folic acid, 0.2 g; nicotinic acid, 3.0 g; calcium pantothenate, 1 .6 g; pyridoxine- HCI, 0. 7 g; riboflavin, 0.6 g; thiamin HCI, 0.6 g; sucrose, 988.42 g 
{Research Diets, New Brunswick, NJ). 
500 IU/gm 
TABLE 3-2 
Diet Composition-Normal ALA study 
" -
Diet Component Control ALA-1 ALA-2 ALA-3 
g/kg 
Casein 1 70 1 70 1 70 1 70 
L-Cystine 3 3 3 3 
Cornstarch 336 336 336 336 
Maltodextrin 1 0  85 85 85 85 
Sucrose 1 14 1 14 1 14 1 14 
Cellulose 57 57 57 57 
Cocoa Butter 40 40 40 40 
Linseed Oil 5 5 5 5 
Palm Oil 56 56 56 56 
Safflower Oil 31 31 31 31 
Sunflower, Trisun1 29 29 29 29 
Total ethyl esters2 7.5 7.4 7.4 7.4 
18: 1 n-9 ethyl ester 6.7 5.2 3.3 0 
18:3 n-3 ethyl ester 0 1 .4 3.3 6.6 
20:4 n-6 ethyl ester 0.4 0.4 0.4 0.4 
20:5 n-3 ethyl ester 0. 1 7  0. 1 7  0. 1 7  0. 1 7  
22:6 n-3 ethyl ester 0.27 0.27 0.27 0.27 
Mineral Mix S1 00263 1 1  1 1  1 1  1 1  
Dicalcium Phosphate 1 5  15  1 5  1 5  
Calcium Carbonate 6 6 6 6 
Potassium Citrate 1 9  1 9  1 9  1 9  
EPA-1 EPA-2 
1 70 1 70 
3 3 
336 336 
85 85 
1 14 1 14 
57 57 
40 40 
5 5 
56 56 
31 31 
29 29 
7.5 7.5 
5.2 3.3 
0 0 
0.4 0.4 
1 .6 3.5 
0.27 0.27 
1 1  1 1  
1 5  1 5  
6 6 
1 9  1 9  
EPA-3 
1 70 
3 
336 
85 
1 14 
57 
40 
5 
56 
31 
29 
7.5 
0 
0 
0.4 
6.8 
0.27 
1 1  
1 5  
6 
1 9  
01 
(0 
TABLE 3-2 
Continued 
Diet Component Control ALA-1 ALA-2 ALA-3 EPA-1 EPA-2 EPA-3 
---------------- g/kg -----------------
Vitamin Mix V1 34014 
Choline Bitartrate 
a -Vitamin E Acetate5 
Tertiary-butyl hydroquinone 
1 1  
2 
0.1 5  
0.03 
1 1  
2 
0 .15 
0.03 
1 High-Oleic acid sunflower oil, Humko Oil Products (Humboldt, TN). 
z All ethyl esters supplied by Nu-Chek Prep (Elysian, MN). 
1 1  
2 
0 . 15  
0.03 
1 1  
2 
0. 15  
0.03 
1 1  
2 
0. 15  
0.03 
1 1  
2 
0. 1 5  
0.03 
1 1  
2 
0. 1 5  
0.03 
0) 
0 
3 Components per Kg Mineral Mix: NaCl, 259 g; magnesium oxide, 41 .9 g, MgS04 • 7 H20, 257.6 g; chromium potassium sulfate · 12  H20, 1 .925 g; cupric carbonate, 1 .05 g; sodium 
fluoride, 0.2 g;  potassium iodate, 0.035 g; ferric citrate, 21 .0 g; manganous carbonate, 12.25 g; ammonium molybdate, 0.3 g; sodium selenite, 0.035 g; zinc carbonate, 5.6 g; sucrose, 
399. 1 05 g. (Research Diets, New Brunswick, NJ). 
4 Components per Kg Vitamin Mix: vitamin A palmitate (500,000 IU/gm) , 0.8 g; cholecalciferol (1 00,000 IU/gm), 1 .0 g; menadione sodium bisulfrte, 0.08 g; biotin (1 .0%), 2.0 g; 
cyanocobalamin (0. 1 % ), 1 .0 g; folic acid, 0.2 g; nicotinic acid, 3.0 g; calcium pantothenate, 1 .6 g; pyridoxine- HCI, 0. 7 g; riboflavin, 0.6 g; thiamin HCI, 0.6 g; sucrose, 988.42 g. 
{Research Diets, New Brunswick, NJ). 
500 IU/gm 
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under an atmosphere of nitrogen to minimize fatty acid oxidation. Animals were 
provided fresh diet each day. 
Background diet 
This research employed two diets as the background diet, the US 17 diet 
(310) (Research Diets, New Brunswick, NJ; diet # D12486B) and a modified 
version of the US17 diet (Research Diets, New Brunswick, NJ; diet # 
D05010801). The US17 diet was originally designed to mimic the Western diet 
with regards to lipid and fatty acid composition (saturated, monounsaturated, and 
polyunsaturated fatty acids). The PUFA content was limited to linoleic acid (LA) 
and a-linolenic acid (ALA) to allow for the addition and evaluation of other dietary 
PUFA (310). One of the experiments used the US17 diet as the background diet 
(High ALA, H-ALA); however, for the other study (Normal ALA, N-ALA) the 
macronutrient distribution was revisited and these values were adjusted to better 
reflect the protein and carbohydrate content of the Western diet (based on % 
kilocalories) (Table 3-3) (311) . The protein content was adjusted from 21 
energy% (original US17 formulation) to 16 energy%, and the carbohydrate 
content was changed from 43.2 energy% to 50 energy%. The background lipid 
content was retained at -34 energy%. While we had no intention of modifying 
the protein and carbohydrate content of the background diet between the studies, 
it was brought to our attention that the protein content of the original US17 diet 
was high fol lowing the first experiment. Although we have no data to suggest 
TABLE 3-3 
Comparison of High ALA and Normal ALA control diets with typical Western consumption 
Diet Component 
Carbohydrate 
Protein  
Fat: 
MUFA 
SFA 
PUFA 
Fatty Acids: 
1 8:2 n-6 
1 8:3 n-3 (ALA) 
20:4 n-6 (AA) 
20:5 n-3 (EPA) 
22:6 n-3 (DHA) 
High-ALA Diet 
energy % 
43.2 
21  
35.8 
14.3 
1 2.9 
8.6 
7.42 
1 .2 
0.08 
0.034 
0.058 
Normal-ALA Diet HED1 
H-ALA 
-------- gms 
50 
1 6  
34 
1 5  
1 1 .6 
7.4 
6.92 1 6.4 
0.6 2.6 
0.08 0. 1 77 
0.034 0.075 
0.054 0. 1 28 
1 Human Equivalent Dose based on energy % equivalent in a 2000 calorie diet. 
2 Source:(31 4)and personal communication: Angela Gajda, Research Diets, New Brunswick, N .J .  
HED Typical Intake 
N-ALA 
50.0 - 52.6 en % (31 1 )  
1 4.6 - 14.9 en % (31 1 )  
32. 1 - 32.3 en % (31 1 )  
1 4  en % (89, 3 12) 
1 1 en % (31 1 )  
7 en % (89, 3 12) 
1 5.3 1 3-1 7 gms (89, 3 12) 
1 .3 1 . 1 -1 .8 gms (6, 7, 3 12) 
0. 1 77 - 1 70 mg (89, 3 1 3) 
0.075 1 00-200 mg, 
0. 1 20 EPA + DHA (6, 7) 
a> 
I\.) 
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otherwise, a search of the literature did not reveal any evidence that the tissue 
phospholipid fatty acid composition would be significantly affected by these 
changes. Nevertheless, this should be considered when evaluating the results. 
Because the typical Western diet contains small amounts of arachidonic 
acid (AA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) (in 
addition to LA and ALA), each of these fatty acids (AA, EPA, and DHA) was 
added to all diets at a dose that modeled typical Western consumption (based 
on caloric density) (Table 3-3) (6, 7, 313, 315). 
Control diets 
Two dietary studies (Normal ALA and High ALA) were designed to test 
the effects of increasing supplemental amounts of dietary ALA or EPA on 
v changes in plasma and erythrocyte phospholipid PUFA content. The Normal 
ALA (N- ALA) study employed a control diet containing ALA at a level of 0.6% of 
energy, whereas the High ALA (H-ALA) study used a control diet containing 
ALA at a level of 1.2 % of energy (Table 3-3). These levels are equivalent to 
1.3 g/d and 2.6 g/d when extrapolated based on caloric density (2000 kcal/d). 
According to the DRls, the Al for ALA is 1.1 g/d for women and 1.6 g/d for men 
(302); which is equivalent to 0.5% -0.7% energy. The LA content of the diets 
was designed to be kept constant at -7 % of energy. 
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Experimental diets 
Experimental diets for both studies were formulated using the control diet 
as a base for supplemented fatty acids. Ethyl esters of ALA or EPA at levels of 
approximately 0.15%, 0.4%, and 0. 7% (w/w), which is equivalent to 0.3%, 0.8%, 
and 1.4 energy%, respectively, were added to both control diets (Table 3-4). 
Supplemental doses were low enough that changes in total fat content between 
. treatment groups would not be expected to confound results attributed to 
supplemental fatty acids. However, in the Normal-ALA study, fatty acids were 
supplemented such that any changes in tissue PUFA phospholipid content could 
only be attributed to the supplemented n-3 PUFA, by adding supplemented ethyl 
esters at the expense of neutral fatty acid oleic acid (18:1 n-9). The upper 
supplemented dose represented by groups ALA-3 and EPA-3 is equivalent to the 
maximum levels of long chain n-3 PUFA recommended by the U.S. Food and 
Drug Administration (3 g/d) (11) (Table 3-4). The fatty acid compositions of the 
experimental diets in the Normal-ALA study and the High-ALA study are 
presented in Tables 3-5 and 3-6. 
Experimental design 
For both studies, mice were randomized into respective diet groups upon 
arrival, by weight. Mice were fed a standard pre-experimental powdered diet mix 
for acclimatization to powdered meals. Mice were then fed treatment diets for 
20-21 days ad libitum. At the end of the diet treatment period mice were fasted 
TABLE 3-4 
Treatment groups and supplemental doses in High and Normal ALA studies 
High-ALA Normal-ALA 
-
Treatment Supplemental Supplemental Supplemental Supplemental 
Group ALA or EPA ALA or EPA HED1 ALA or EPA ALA or EPA 
wt %  energy % gms wt %  energy % 
ALA-1 0.1 5 0.3 0.67 0. 1 5  0.3 
ALA-2 0.40 0.80 1 .78 0.33 0.66 
ALA-3 0.73 1 .45 3.22 0.66 1 .32 
EPA-1 0. 1 5  0.3 0.67 0. 1 5  0.3 
EPA-2 0.41 0.82 1 .82 0.33 0.66 
EPA-3 0.69 1 .39 3. 1 0  0.66 1 .32 
1 Human Equivalent Dose (HED) based on energy% equivalence in a 2000 calorie human diet. 
HED 
gms 
0.67 
1 .47 
2 .93 
0.67 
1 .47 
2.93 
0) 
0, 
0) 
0) 
TABLE 3-5 
Fatty acid composition of diets used in the High-ALA study1 
Fatty Acid Control ALA-1 ALA-2 ALA-3 EPA-1 EPA-2 EPA-3 
mole % 
1 0:0 0.07 ND 0.07 ND ND ND ND 
1 2:0 1 .23 1 .06 1 . 1 5  1 .06 1 . 1 9  1 . 1 9  1 .02 
1 4:0 1 . 1 3  1 . 16  1 . 1 3  1 .09 1 .20 1 . 1 9  1 . 1 1  
1 6:0 23.95 24.21 24.01 23.59 24.49 24. 1 2  23. 1 0  
1 6: 1  0. 1 7  0. 1 7  0 . 1 7  0. 1 6  0 . 1 7  0. 1 7  0. 1 6  
1 8:0 1 1 .48 1 1 .45 1 1 . 1 2  1 1 .06 1 1 .06 1 1 .08 1 1 .21 
1 8: 1  (n-9) 38.43 37.75 37.04 36.70 38. 1 7  37.74 36.58 
1 8: 1  (n-7) 0.57 0.54 0.55 0.54 0.57 0.56 0.55 
1 8:2 (n-6) 1 8.29 18. 1 9  1 7.95 1 7.61 1 7.94 1 7.66 1 7.79 
1 8:3 (n-3) 3.32 4 . 14  5.50 6.90 3.20 3. 1 8  3.39 
20:0 0.46 0.46 0.45 0.45 0.45 0.46 0.45 
20: 1 0. 1 3  0. 1 3  0. 1 3  0. 1 3  0. 1 3  0. 1 3  0. 1 2  
20:4 (n-6) 0. 1 9  0. 19  0. 1 9  0. 1 8  0. 1 9  0. 1 9  0. 1 9  
20:5 (n-3) 0.09 0.09 0. 1 0  0.09 0.79 1 .88 3.84 
22:0 0.22 0.22 0.2 1 0.21 0.21 0.2 1 0.22 
22.5 (n-3) 0. 12  0. 1 1  0. 1 1  0 . 1 1 0 . 1 1 0 . 1 1 0 . 1 1 
22:6 (n-3) 0. 1 3  0. 1 3  0. 1 3  0. 1 3  0. 1 3  0. 1 2  0. 1 3  
TABLE 3-5 
Continued 
Fatty Acid Control ALA-1 ALA-2 ALA-3 EPA-1 
mole % 
Total saturated FA 38.55 38.55 38. 1 4  37.45 38.60 
Total MUFA 39.30 38.59 37.89 37.53 39.04 
Total PUFA 22. 1 6  22.85 23.97 25.02 22.36 
Total {n-6) 1 8.49 1 8.38 1 8. 1 4  1 7.79 1 8. 1 3  
Total {n-3) 3.67 4.47 5.83 7.23 4.23 
P:S ratio 0.57 0.59 0 .63 0.67 0.57 
{n-3):(n-6) ratio 0.20 0.24 0.32 0.41 0.23 
1 Powder diets were processed using a modified Bligh and Dyer fatty acid analysis (3 16) (see full description in methods section). 
2 Abbreviations: ND- not detected. 
EPA-2 
38.25 
38.60 
23. 1 6  
1 7.86 
5.30 
0.60 
0.30 
EPA-3 
37. 1 0  
37.42 
25.48 
1 8.00 
7.48 
0.68 
0.42 
O') 
--..J 
TABLE 3-6 
Fatty acid composition of diets used in the Normal-ALA study1 
Fatty Acid Control ALA-1 ALA-2 ALA-3 EPA-1 
mole % 
1 0:0 0.1 5  0.07 0.1 1 0.1 3  0.1 2  
1 2:0 1 .94 1 .73 1 .43 1 .61 1 .79 
1 4:0 1 .26 1 .26 1 .20 1 .28 1 .23 
1 6:0  22.81 23.01 22.61 23.06 22.87 
1 6: 1  0.1 6 0. 1 6  0.1 5 0.1 6  0.1 5  
1 8:0 1 0.84 1 1 . 16  1 1 .36 1 1 .20 1 1 .25 
1 8: 1  (n-9) 41 .25 40.35 39.67 37.51 40.36 
1 8: 1  (n-7) 0.61 0.59 0.60 0.60 0.59 
1 8:2 (n-6) 1 7.84 1 7.71 1 7.84 1 7.66 1 7.67 
1 8:3 (n-3) 1 .73 2.55 3.54 5.41 1 .71  
20:0 0.45 0.46 0.48 0.46 0.47 
20: 1 0.1 4 0. 1 4  0.1 4  0.1 4  0.1 4  
20:4 (n-6) 0.21 0.21 0.21 0.21 0.21 
20:5 (n-3) 0.1 0  0.1 0 0.1 1 0.09 0.9 1 
22:0 0.22 0.22 0.24 0.22 0.23 
22.5 (n-3) 0.13  0. 1 3  0.1 4  0.1 3  0.1 3  
22:6 (n-3) 0.1 7  0. 1 5  0.1 6  0.1 5  0.1 5  
EPA-2 
0. 1 3  
1 .66 
1 .24 
22.89 
0.1 6 
1 1 .32 
39 .45 
0.57 
1 7.59 
1 .71 
0.47 
0.1 4 
0.22 
1 .95 
0.23 
0.1 3  
0. 1 5  
EPA-3 
ND 
1 .74 
1 .1 7  
22.48 
0.1 5  
1 1 .45 
37.68 
0.60 
1 7.74 
1 .72 
0.49 
0. 1 4  
0 .24 
3.87 
0.24 
0.1 4 
0. 1 6  
a, 
co 
"-----
TABLE 3-6 
Continued 
Fatty Acid Control ALA-1 ALA-2 ALA-3 EPA-1 
mole % 
Total saturated FA 37.67 37.91 37.44 37.96 37.97 
Total MUFA 42. 1 5  41 .24 40.56 38.40 41 .24 
Total PUFA 20. 1 8  20.86 21 .99 23.64 20.78 
Total (n-6) 1 8.05 1 7.92 1 8.05 1 7.87 1 7.88 
Total (n-3) 2 . 14 2.94 3.94 5.77 2.90 
P:S ratio 0.54 0.55 0.59 0.62 0.55 
(n-3): (n-6) ratio 0. 1 2  0. 1 6  0.22 0.32 0. 1 6  
1 Powder diets were processed using a modified Bligh and Dyer fatty acid analysis (31 6) (see full description in methods section). 
EPA-2 
37.93 
40.32 
21 .75 
1 7.81 
3.94 
0.57 
0.22 
EPA-3 
37.56 
38.57 
23.87 
1 7.98 
5.89 
0.64 
0.33 
CJ) 
c.o 
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overnight and killed via carbon dioxide asphyxiation, followed by blood and tissue 
sample collection. 
Blood collection 
Animals were exsanguinated via cardiac puncture using standard 
anticoagulant (dried lithium heparin syringes (Portex brand, Smiths Medical, 
Keene, NH) or 3.8% sodium citrate). Collected blood was transferred to 
microcentrifuge tubes and inverted. For each experiment, anticoagulated blood 
was centrifuged at 660 x g for 4 minutes at room temperature (317). Platelet rich 
plasma (PRP) was removed and used for plasma fatty acid analysis. Remaining 
packed erythrocytes were suspended in 1 ml 0.9% saline, vortexed, and used for 
erythrocyte fatty acid analysis. 
Plasma and erythrocyte phospholipid fatty acid analysis 
Fatty acids were extracted from plasma and erythrocytes using a modified 
Bligh and Dyer analysis (316). Briefly, total lipid extracts were obtained using a 
1 :2 (v/v) chloroform/methanol mixture and 1,2-diheptadecanoyl-sn-glycero-3-
phosphorylcholine added initially as an internal standard. The lipid soluble layer 
was separated twice using saturated sodium chloride solution and chloroform 
and the lower layer was removed. Removed lipid extracts were dried under an 
atmosphere of nitrogen. Dried total lipid was resuspended in a small volume of 
chloroform and separated into respective phospholipids, neutral lipids, and free 
fatty acids on High Performance Thin-Layer Chromatography plates ( silica gel 
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60, Merck, Darmstadt, Germany). An 8: 1 (v/v) chloroform/methanol solvent 
system was used for HPLC separation. The phospholipid band was scraped 
from the origin and saponified with 0.5 mol/L sodium hydroxide in methanol for 
15 minutes at 86°C. Fatty acids were then methylated using 14% boron 
trifluoride in methanol for 10 minutes at 86°C. Following acidification with 0. 7 
mol/L hydrochloric acid in methanol, fatty acid methyl esters were extracted twice 
with hexane, dried under nitrogen, resuspended in a small volume of hexane, 
and injected onto a Hewlett Packard model 5890 series 1 1  gas chromatograph 
(Palo Alto, CA) with flame ionization detector. Fatty acids were separated using 
a DB 23, 33m, .25mm diameter capillary glass column packed with fused silica (J 
& W Scientific, Folsom, CA). Column temperature was programmed to rise from 
160° C at a rate of 3.5 degrees per minute up to a final temperature of 250°C. 
Hydrogen was used as the carrier gas. Fatty acid peaks were identified by 
comparison to known fatty acid standards (Nu-Chek Prep, Elysian, MN) and peak 
area of internal standard 17:0 was used to determine mole percent of sample 
peaks. 
Identification and selection of cl inical trials 
This research was designed to evaluate the impact of dietary n-3 PUFA on 
fatty acid changes in mice and humans in comparable tissues. While searching 
for human data for comparison, the following keywords were used individually 
and in various combinations: plasma phospholipids, erythrocyte phospholipids, 
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human, omega-3, n-3, fatty acids, ALA, a-linolenic acid, EPA, eicosapentaenoic 
acid, DHA, docosahexaenoic acid, supplementation, and intervention. The 
search strategy was not designed to be exhaustive, but to provide sufficient data 
revealing the overall landscape and general pattern of the effects of dietary n-3 
PUFA in humans for comparison to murine effects. Additional sources were 
identified from cited references and review articles. Initial searches yielded -60 
studies reporting plasma phospholipid changes and -25 studies reporting 
erythrocyte phospholipid changes were analyzed. Papers included in the study 
had to report baseline tissue fatty acid compositions and changes in the tissue 
post intervention. Dietary interventions ranged from 1 week to 12 months with 
most interventions lasting between 1-3 months. The typical human study 
involved omega-3 supplementation given in addition to a general diet. 
Supplementation of omega-3 fatty acids could be in form of ethyl esters, n-3 
PUFA containing capsules, vegetable oils (i.e. flaxseed oil, soybean, canola, 
etc .. ) fish and fish oil, so long as the supplemented n-3 PUFA intakes could be 
determined. All blood samples for fatty acid analysis had to be collected 
following a fast. Both international and domestic studies were included. Studies 
were not weighted on the basis of participant number. Exclusion criteria 
included invasive interventions (such as surgery), subjects less than 18 years of 
age, and women who were pregnant. After review and exclusion based on the 
above factors, roughly 40 studies remained that were used for comparison to 
murine data. 
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Presentation of the human data 
The human data are presented in ascending order along the x-axis by 
increasing energy% of the specified supplemented fatty acid, with the y-axis 
representing the percent change in a specified plasma or erythrocyte 
phospholipid fatty acid as indicated. Difference in pre and post tissue measures 
were used to calculate percent change from original values. 
Statistical analyses 
Phospholipid fatty acid content in plasma and erythrocytes was compared 
across treatment groups using one-way analysis of variance (ANOVA), followed 
by Fisher's least significant difference post-hoc test to determine significant 
differences between groups. Data was considered significant at p < 0.05. 
Statistical analysis was performed with SPSS software (Chicago, IL). 
3.4 Results 
Analysis of intake and weights 
Weekly group weight means (in grams) were consistent between groups 
and between studies (Figure A-1 ). Average daily food intake was also 
consistent between groups (Figure A-2). 
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Changes in phospholipid fatty acids 
At the end of the experimental period, fatty acid composition was 
determined in plasma and erythrocyte phospholipids for both studies (N-ALA and 
H-ALA). Differences in fatty acid composition between experimental groups and 
control groups were determined for each PUFA of interest and plotted as percent 
change. Murine data was compared to data from archival human clinical trials in 
comparable tissues. For each human study, changes in plasma/serum or 
erythrocyte phospholipid fatty acids from baseline to post intervention were 
determined and, likewise, were plotted as percent change. For graphical 
representation, murine and human data representing change in the same tissue 
and fatty acid were combined and ordered along the x-axis based on ascending 
amounts of supplemented omega-3 fatty acid (in energy%). 
Effects of ALA supplementation on changes in plasma and erythrocyte 
phospholipki fatty acids 
Plasma phospholipid EPA content in N-ALA mice supplemented with 
increasing amounts of ALA responded in a dose dependent manner (Table 3-7). 
The content of EPA in plasma was relatively low in the control group (0. 1 mol % ) 
and increased 2, 5, and 8 fold following ALA supplementation of 0.3%, 0.66%, 
and 1 .32% of energy, respectively. DHA was modestly higher by 17% and 2 1  % 
in the ALA -2 and ALA -3 supplemented groups, respectively. Similar trends 
were observed with chan��es in EPA in erythrocyte phospholipids; however, 
significant differences were only observed in the in the highest ALA 
TABLE 3-7 
Plasma phospholipid fatty acid composition by treatment group in the Normal ALA study1 
Fatty Acid Control ALA-1 ALA-2 ALA-3 EPA-1 EPA-2 EPA-3 
n = 5 4 5 5 5 4 5 
mole % of total fatty acids 
1 4:0 0.3 ± 0. 1 0.2 ± 0.0 0.4 ± 0 .1  0 .5 ± 0. 1 0.4 ± 0. 1 0.4 ± 0.2 0.3 ± 0.2 
1 6:0 27.8 ± 0.78b 26.6 ± 0.68 28.7 ± 0.2bc 28.8 ± 0.4bc 29.6 ± 0.6c 29.7 ± 0f 28.9 ± 0.5c 
16 : 1  0.4 ± 0 . 1  0 .3  ± 0 .1  0.7 ± 0.2 0.9 ± 0.2 0.8 ± 0. 1 0.7 ± 0.2 0.7 ± 0.3 
1 8:0 1 7.9 ± 1 .2b 1 8.3 ± 0.6b 14.5 ± 0.58 14.6 ± 0.68 1 3.9 ± 0.58 14.5 ± 0.68 1 5.2 ± 0.7a 
1 8: 1  (n-9) 1 2.6 ± 0.7 1 2.8 ± 0.5 1 1 .7 ± 0.5 12 . 1 ± 0.7 1 2.2 ± 0.7 1 1 .7 ± 0.7 1 1 .8 ± 0.9 
1 8: 1  (n-7) 0.8 ± 0.0 0.8 ± 0.2 0.8 ± 0.0 0.9 ± 0.1  0 .7 ± 0 . 1  0 .8  ± 0.0 0.8 ± 0.0 
1 8:2 (n-6) 17.9 ± 0.58 21 .3 ± 0.9b 1 8.6 ± 0.58 1 8.4 ± 0.78 19 . 1  ± 0.38 1 8.3 ± 0.1 8 1 8.5 ± 0.38 
1 8:3 (n-6) 0.3 ± 0. 1 cd 0.2 ± 0.08b o.3 ± o.oa1 0.3 ± 0.1 bc 0.4 ± 0.0d o.3 ± o.obcd 0.2 ± 0 . 1 8 
1 8:3 (n-3) 0 .1  ± 0.08 0.1  ± 0.08 o.3 ± o.ob 0.4 ± 0.1 b 0. 1 ± 0.1 8 0.1  ± 0. 1 8 0. 1 ± 0.18 
20:0 < 0.1 0.2 ± 0.0 0.1 ± 0.0 0.2 ± 0.0 0.1 ± 0.0 0 . 1 ± 0. 1  0. 1 ± 0 . 1  
20: 1  0 . 1  ± 0.0 0 .1  ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0. 1 ± 0 . 1  0 . 1 ± 0. 1  0 .1  ± 0 . 1  
20:2 0. 1 ± 0.08b 0.2 ± 0. 1 bc 0.2 ± o.obc 0.2 ± 0.0c 0. 1 ± 0.1 8b 0. 1 ± 0. 1 ab < 0 . 1 8 
20:3 (n-6) 1 . 1 ± 0.08 1 .7 ± 0. 1
b 1 .4 ± 0.08 1 .8 ± 0 .1 b 1 .2 ± 0. 1 8 1 .4 ± 0. 1 8 1 .3 ± 0 . 1 8 
20:4 (n-6) 12.8 ± 0.6cd 9.7 ± 0.88b 1 2.9 ± 0.2d 1 0.8 ± 0.4b 1 1 .3 ± 0.7bc 1 0.4 ± 0.6b 8.2 ± 0.48 
20:5 (n-3) 0.1 ± 0.1 8 0.2 ± 0.0b 0.5 ± 0.0bc o.8 ± o.oa1 o.9 ± o.od 1 .7 ± 0.28 3.2 ± 0.2' 
22:4 (n-6) 0.1 ± 0.08 0.2 ± 0. 1 b 0.1  ± 0.08 0.1 ± 0.08 ND N D  ND 
22.5 (n-6) 0.2 ± 0 .1 b 0.3 ± 0.2b < 0.1 8 < 0 . 1 8 ND N D  N D  
22:5 (n-3) 0.2 ± 0 .1 8 0.3 ± 0 .1 8b o.4 ± o.ob 0.5 ± 0.0c 0.6 ± o.oc 0.9 ± 0. 1 d 1 .3 ± 0.08 
22:6 (n-3) 7.1 ± 0.28 6.4 ± 0.38 8.3 ± 0. 1 b 8.6 ± 0.1 b 8.8 ± 0.3b 9.0 ± 0.5b 9.3 ± 0.4b 
Total (n-3) 7.6 ± 0.38 7.3 ± 0.38 9.6 ± 0 .1 b 1 0.4 ± 0. 1 b 1 0.3 ± 0.3b 1 1 .7 ± 0.4c 1 3.9 ± 0.4d 
Total (n-6) 32.4 ± 0.6cd 33.3 ± 0.7'18 33.3 ± o.5de 31 .3 ± o.ric 31 .9 ± 0.6bcd 30.3 ± 0.7b 28.2 ± 0.78 
(n-3):(n-6) ratio 0.2 ± 0.08 0.2 ± 0.08 o.3 ± o.ob 0.3 ± o.oc 0.3 ± o.oc o.4 ± o.od 0.5 ± 0.08 
1 Results are means ± SEM. Difference in letter superscripts within the same row indicate statistical significance, p <.05. 
2 Abbreviations: ALA- alpha- linolenic acid, EPA- eicosapentaenoic acid, ND- not detected 
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supplemented group (ALA- 3) (Table 3-8). As observed in plasma, DHA levels in 
erythrocytes were modestly higher in the ALA-2 and ALA-3 supplemented groups 
by 13% and 11 %, respectively. 
When the level of ALA in the background diet was doubled (1.2% energy) 
(H-ALA), effects on tissue n-3 PUFA content were attenuated (compared to the 
N-ALA study) following progressive supplementation of ALA (Table 3-9 and 
Table 3-1 0). In plasma phospholipids, the changes in EPA levels were only 2.0 
and 2.7 fold higher in the ALA-2 and ALA-3 supplemented groups, while there 
were no significant changes in DHA. 
Comparison of changes in mouse and human phospholipid fatty acids following 
ALA supplementation 
When compared to archival human data, the changes observed in the 
mouse phospholipid EPA were greater than human changes when the 
supplemented doses in the N-ALA groups were matched to human data by 
caloric density of supplemented fatty acid (Figure 3-1 and Table 3-1 1 ). 
However, the responses observed in the mouse diets containing the higher 
background levels of ALA (H-ALA groups) appear to be better correlated with the 
human data with respect to changes in EPA levels in both plasma and 
erythrocyte phospholipids. ALA had a marginal effect on DHA change in 
plasma/serum phospholipids in both mice and humans except for one study, 
Ghafoorunissa et al.(318), however, it appeared that this was due to low initial 
TABLE 3-8 
Erythrocyte phospholipid fatty acid composition by treatment group in the Normal ALA study1 
Fatty Acid Control ALA-1 ALA-2 ALA-3 EPA-1 EPA-2 EPA-3 
n = 5 4 5 5 5 5 5 
mole % of total fatty acids 
1 4:0 0.3 ± 0.0 0.3 ± 0.0 0.3 ± 0.0 0.2 ± 0.0 0.3 ± 0.0 0.3 ± 0.0 0.2 ± 0 .1  
1 6:0 30.2 ± 0. 1 8b 30.0 ± 0 .1 8b 29.6 ± 0.38 29.6 ± 0.28 29.9 ± 0.28b 30.6 ± 0.5bc 31 .3  ± 0.6c 
1 6: 1  0.4 ± 0.0 0.3 ± 0.0 0.3 ± 0.0 0.4 ± 0.0 0.4 ± 0.0 0.3 ± 0.0 0.3 ± 0. 1 
1 8:0 1 1 .8 ± 0.3 1 2.0 ± 0.0 1 1 .4 ± 0 .1  1 1 .8 ± 0.4 1 2.7 ± 1 .2 1 2.2 ± 0.1 1 2.0 ± 0.3 
1 8: 1  (n-9) 14 .7 ± 0.2 1 5.0 ± 0.0 1 4.6 ± 0.2 14.7 ± 0.2 1 6.0 ± 1 .4 1 5. 1  ± 0 .1  1 5.0 ± 0.2 
1 8: 1  (n-7) 0.9 ± 0.1 0.9 ± 0.0 0.9 ± 0.0 0.9 ± 0.0 0.9 ± 0. 1 0.8 ± 0.0 0.8 ± 0.0 
1 8:2 (n-6) 1 0.6 ± 0.7 1 1 .2 ± 0.2 1 1 .0 ± 0.6 1 2.3 ± 0 .1  1 2.5 ± 0.8 1 1 .2 ± 0.3 1 1 . 1 ± 0.2 
1 8:3 (n-6) 0.1 ± 0.0 0.2 ± 0.0 0.1 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0. 1 ± 0.0 
1 8:3 (n-3) ND 0.1  ± 0.08 0.2 ± o.ob 0.3 ± 0.0
c N D  N D  N D  
20:0 0.1 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.1 ± 0.0 
20: 1  0.3 ± 0.0b 0.3 ± 0.0b o.3 ± o.ob 0.3 ± 0.0b o.4 ± o.ob 0.3 ± 0.0b 0.2 ± 0 .1 8 
20:2 o.3 ± a.ob 0.3 ± 0.0b o.3 ± o.ob 0.3 ± 0.0b o.3 ± o.ob 0.3 ± O.Ob 0.2 ± 0 .1 8 
20:3 (n-6) 1 .3 ± 0 . 1 c 1 .4 ± 0. 1 c 1 .2 ± 0. 1 c 1 .3 ± o.oc 1 .3 ± 0 .1 c 1 . 1 ± o.ob 1 .0 ± 0.08 
20:4 (n-6) 1 8.0 ± 0.8d 1 6.6 ± 0.300 1 7.6 ± 0.8d 1 5.7 ± 0.3c 1 6.2 ± 0.8c 1 3.2 ± 0.4b 1 1 .4 ± 0.38 
20:5 (n-3) 0.3 ± 0.0
8 0.4 ± 0.08 0.5 ± 0 . 1 8 o.9 ± o.ob 1 .6 ± 0 . 1 c 2.4 ± 0. 1 d 4.5 ± 0.28 
22:4 (n-6) 1 .6 ± 0 . 1 8 1 .4 ± O.Od8 1 .4 ± 0.1 d 1 .2 ± o.oc 1 .3 ± 0. 1 c 1 .0 ± 0. 1 b 0.9 ± 0.08 
22:5 (n-6) 0.8 ± 0. 1
d 0.1 ± 0.000 0.7 ± 0 .1 cd 0.5 ± 0.0bc 0.5 ± 0.08bc 0.4 ± 0.08b 0.3 ± 0 .1 8 
22:5 (n-3) 0.6 ± 0.1
8 0.8 ± 0.08b 0.9 ± 0 .1 b 1 . 1 ± o.oc 1 .4 ± 0 .1 c 1 .7 ± 0.1 d 2.4 ± 0.1 8 
22:6 (n-3) 7.5 ± 0.28 7.9 ± 0.3ab 8.5 ± 0.3bc 8.3 ± 0.1 bc 9.1 ± 0.5bc 8.7 ± 0.2c 8.2 ± 0.2bc 
Total (n-3) 8.4 ± 0.38 9.2 ± 0.28 1 0. 1  ± 0.4b 1 0.6 ± 0.2bc 1 2. 1  ± Of 1 2.8  ± 0.3d 1 5. 1  ± 0.58 
Total (n-6) 32.4 ± 0.58 3 1 .5 ± 0.2de 32. 1  ± 0.3de 31 . 1  ± 0.4d 32. 1  ± 1 .8c 27. 1 ± 0.3b 24.8 ± 0.58 
(n-3):(n-6) ratio 0.3 ± 0.08 0.3 ± 0.0b 0.3 ± O.Obc 0.3 ± o.oc 0.4 ± 0.0d 0.5 ± 0.0 0.6 ± 0.08 
1 Results are means ± SEM. Different letter superscripts within the same row indicate statistical significance, p <.05. 
2 Abbreviations: ALA- alpha- linolenic acid, EPA- eicosapentaenoic acid, N D- not detected. 
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TABLE 3-9 
Plasma phospholipid fatty acid composition by treatment group in the High ALA study 1 
Fatty Acid Control ALA-1 ALA-2 ALA-3 EPA-1 EPA-2 
n =  5 5 5 5 5 5 
mole % of total fatty acids 
1 4:0 0.2 ± 0.1 0.3 ± 0. 1 0.3 ± 0. 1 0.4 ± 0. 1 0 . 1  ± 0. 1 0.4 ± 0.2 
1 6:0 30.5 ± 0.1 30.9 ± 0.5 30.6 ± 0.5 30.6 ± 0.4 31 . 1 ± 0.4 31 .2 ± 0.2 
1 6: 1  0.3 ± 0.0 0.4 ± 0.0 0.3 ± 0. 1 0.4 ± 0.0 0.4 ± 0.0 0.3 ± 0. 1 
1 8:0 1 6. 1  ± 0. 1 1 5.5 ± 0.4 16 . 1  ± 0.2 1 5.5 ± 0.3 1 5.2 ± 0.3 1 5.2 ± 0.2 
1 8: 1  (n-9) 1 0.4 ± 0.2 9.7 ± 0. 1 9.8 ± 0.3 9.8 ± 0.4 1 0.2 ± 0.2 9.9 ± 0.3 
1 8: 1  (n-7) o.6 ± o.ocd 0.6 ± o.oab o.6 ± o.obcd 0.6 ± o.oab 0.1 ± o.od o.6 ± o.obc 
1 8:2 (n-6) 1 9.4 ± 0.2 1 7.9 ± 0.5 1 9. 1  ± 0.8 1 9.4 ± 0.4 1 8.7 ± 0.5 1 9.3 ± 0.4 
1 8:3 (n-6) 0.4 ± 0.0 0.3 ± 0 . 1  0 .3  ± 0. 1 0.3 ± 0. 1 0.3 ± 0.0 0.3 ± 0.0 
1 8:3 (n-3) ND 0. 1 ± 0. 1 a 0.1 ± 0. 1 a 0.4 ± o.ob 0. 1 ± 0.1 a 0.1  ± 0. 1 a 
20:2 ND ND < 0 . 1  ND ND ND 
20:3 (n-6) 1 .0 ± 0.0 1 .0 ± 0. 1 1 . 1 ± 0.1 1 . 1 ± 0. 1 1 .0 ± 0. 1 1 .0 ± 0. 1 
20:4 (n-6) 1 1 .8 ± 0.2de 1 2.7 ± 0.38 1 0.9 ± 0.5cd 1 0.7 ± 0.2c 1 1 . 1 ± 0. 1 cd 9.5 ± 0.4b 
20:5 (n-3) 0.3 ± o.oa 0.4 ± o.oab o.6 ± o.obc o.8 ± o.ocd o.9 ± o.od 1 .7 ± 0. 1 ° 
22:5 (n-3) 0.4 ± o.oa 0.5 ± o.oa o.5 ± o.ob o.6 ± o.ob o.6 ± o.ob 0.9 ± o.oc 
22:6 (n-3) 8.5 ± 0.1 9.9 ± 0.4 9.6 ± 0.6 9.4 ± 0.2 9.7 ± 0.3 9.7 ± 0.3 
Total (n-3) 9.2 ± 0.1 8 1 0.8 ± 0.4b 1 0.9 ± 0.6b 1 1 .2 ± 0.2b 1 1 .4 ± 0.3bc 1 2.3 ± 0.3c 
Total (n-6) 32.6 ± 0. 1 d 31 .8 ± 0 .4cd 31 .4 ± 0.7bcd 31 .5 ± o.4cd 31 . 1  ± 0.4bc 30. 1 ± 0.5b 
(n-3):(n-6) ratio 0.3 ± o.oa o.3 ± o.ob 0.4 ± 0.0b 0.4 ± 0.0b 0.4 ± 0.0bc 0.4 ± o.oc 
1 Results are means ± SEM. Different alphabetic superscripts denote statistical significance within each fatty acid , p <.05. 
2 Abbreviations: ALA- alpha- linolenic acid , EPA- eicosapentaenoic acid, ND- not detected. 
EPA-3 
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0.2 ± 0. 1 
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TABLE 3-10 
Erythrocyte phospholipid fatty acid composition by treatment group in the High ALA study 1 
Fatty Acid Control ALA-1 ALA-2 ALA-3 EPA-1 EPA-2 EPA-3 
n = 5 5 5 5 5 5 5 
mole % of total fatty acids 
1 4:0 0 .1  ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0. 1 0.2 ± 0.0 0.2 ± 0.0 
1 6:0 32.0 ± 0.1 ab 31 .6 ± 0.2 a 32.2 ± 0.2 b 32. 1  ± 0.2 b 32. 1 ± 0. 1 b 32.2 ± 0.2 b 33.0 ± 0. 1 c 
1 6: 1  0.3 ± 0.0 0 .3 ± 0.0  0.3 ± 0.0 0.3 ± 0.0 0.3 ± 0.0 0.3 ± 0.0 0.3 ± 0.0 
1 8:0 1 2.3 ± 0.0 1 2 .5 ± 0. 1 1 2.3 ± 0. 1 1 2.2 ± 0. 1 1 2.2 ± 0 . 1  1 2.3 ± 0.1  1 2.3 ± 0. 1 
1 8: 1  (n-9) 1 4.2 ± 0 . 1 bc 1 3.8 ± 0.0 1 4. 1  ± 0. 1 ab 1 4. 1  ± 0.1 ab 1 4.3 ± 0.2bc 1 4.4 ± 0 . 1
bc 1 4.6 ± 0.1 c 
1 8: 1  (n-7) o.9 ± o.ob 0.9 ± o.oab o.9 ± o.ob o.9 ± o.ob o.9 ± o.ob 0.9 ± o.oab 0.8 ± o.o a 
1 8:2 (n-6) 1 1 .0 ± 0. 1 1 0.9 ± 0.3 1 1 .3 ± 0.3 1 1 .5 ± 0.1 1 1 .0 ± 0.3 1 1 . 1  ± 0.2 1 0.4 ± 0. 1 
1 8:3 (n-6) 0 .1  ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 
1 8:3 (n-3) 0 . 1  ± o.oa 0.2 ± o.oa 0.3 ± o.oc o.3 ± o.ob 0.2 ± o.oa 0. 1 ± o.oa 0.1  ± 0.08 
20: 1 0.3 ± 0.0b o.3 ± o.ob o.3 ± o.ob 0.3 ± o.oc o.3 ± o.ob 0.3 ± 0.08 0.3 ± 0.08 
20:2 0.3 ± 0.08 o.3 ± o.od o.3 ± o.ocd o.3 ± a.ode o.3 ± o.ob 0.3 ± o.oc 0.3 ± 0.08 
20:3 (n-6) 1 .3 ± o.oc 1 .3 ± o.oc 1 .3 ± o.oc 1 .3 ± o.oc 1 .2 ± o.oc 1 . 1 ± 0.0b 1 .0 ± 0.08 
20:4 (n-6) 1 5.2 ± 0.2d 1 5.5 ± 0.2d 1 4.0 ± 0.2c 1 3.8 ± 0.2c 1 3.8 ± 0.2c 1 2. 1  ± 0.2b 9.8 ± 0.08 
20:5 (n-3) 0.5 ± 0.08 0.6 ± 0.08 o.8 ± o.ob 1 .0 ± o.ob 1 .5 ± o.oc 2.8 ± O.Od 4.8 ± 0.28 
22:4 (n-6) 1 .2 ± o.od 1 .2 ± o.od 1 .0 ± o.oc 1 .0 ± o.oc 1 .0 ± o.oc o.8 ± o.ob 0.7 ± 0.08 
22:5 (n-6) o.5 ± o.ot 0.4 ± 0.08 0.3 ± o.oc o.3 ± o.ocd o.3 ± o.od 0.2 ± o.ob 0.2 ± 0.08 
22:5 (n-3) 1 .2 ± 0.08 1 .2 ± 0.08 1 .4 ± o.oc 1 .5 ± o.ob 1 .6 ± o.oc 2.0 ± o.od 2.6 ± 0. 1 8 
22:6 (n-3) 8.2 ± 0.08 8.6 ± 0. 1 b 8.7 ± 0.2b 8.8 ± 0. 1 b 8.6 ± 0. 1 b 8.6 ± 0. 1 b 8.5 ± 0. 1 ab 
Total (n-3) 1 0.0 ± 0. 1 a 1 0.5 ± 0. 1 b 1 1 .2 ± 0.2d 1 1 .6 ± 0 . 1 c 1 1 .8 ± 0 . 1 d 1 3.6 ± 0.28 1 6.0 ± 0.2f 
Total (n-6) 29.3 ± 0. 1 8 29.4 ± 0. 1 8 28. 1 ± 0.2cd 27.9 ± 0.2d 27.5 ± 0. 1 c 25.5 ± 0.3b 22.2 ± 0.28 
(n-3): (n-6) ratio 0.3 ± 0.08 0.4 ± 0.08 o.4 ± o.obc o.4 ± o.ob 0.4 ± o.oc o.5 ± o.od 0.7 ± 0.28 
1 Results are means ± SEM. Different alphabetic superscripts denote statistical significance within each fatty acid, p < .05. 
2 Abbreviations: ALA- alpha- linolenic acid, EPA- eicosapentaenoic acid, ND- not detected. 
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Figure 3-1: Percent change in plasma/serum phospholipid EPA by increasing 
ALA supplementation in energy%. Murine data is represented by red bars (N­
ALA) or red speckled bars (H-ALA), with human studies intermingled 
horizontally. Numerical superscripts correspond to human study descriptions in 
Table 3-11. 
TABLE 3-1 1 
Human ALA supplementation studies used in Figure 3-1 
Vertical bar 
in Figure 3-1 
1 
2, 6 
3, 4 
5 
7, 1 1  
8 
9, 1 4  
1 0  
1 2  
1 3  
1 5  
1 6, 1 7  
1 8  
Author 
Sinclair 
Seppanen-Laakso 
James 
Thies 
Finnegan 
Wallace 
Li 
Valsta 
Mest 
Mantzioris 
Cunnane 
Singer1 
Beitz 
Supplemental 
Energy% ALA 
0.2 
0.22, 0.7 
0.31 , 0.62 
0.65 
1 . 1 5, 2.89 
1 .2 
1 .21 , 5.5 
1 .6 
4 
4.9 
6 
1 3.6 
14.7 
Citation 
(31 9) 
(320) 
(32 1 )  
(322) 
(323) 
(324) 
(325) 
(326) 
(327) 
(328) 
(329) 
(330) 
(331 ) 
1 Supplemental values were the same with 16 representing normolipidemics and 1 7  representing hyperlipidemics. 
DHA levels, thus the potential for increase may have been greater than other 
human studies (Figure 3-2 and Table 3-1 2). 
Effects of EPA supplementation on changes in plasma and erythrocyte 
phospholipid fatty acids 
Plasma phospholipid EPA content in N- ALA mice supplemented with 
increasing amounts of EPA changed significantly in a dose dependent manner 
(Table 3-7). The content of EPA in plasma phospholipids was increased 9, 17, 
and 32 fold following EPA supplementation of 0.3%, 0.66%, and 1.32% of 
energy, respectively. The changes observed in DHA in the lowest EPA 
supplemented group (EPA-1) were equivalent to the changes observed in the 
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Figure 3-2: Percent change in plasma/serum phospholipid DHA by increasing 
ALA supplementation in energy%: (A) Ghafoorunissa (31 8) in yellow and 
(B) Excluding Ghafoorunissa, for comparison. Murine data is represented by red 
bars (N-ALA) or red speckled bars (H-ALA), with human studies intermingled 
horizontally. Numerical superscripts correspond to human study. descriptions in 
Table 3-12 (A and 8). 
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TABLE 3-12 
Human ALA supplementation studies used in Figure 3-2 
DHA studies Vertical bar Author Supplemental Citation 
in Figure 3-2 Energy% ALA 
A) 1 Sinclair 0.2 (319) 
2, 10 Seppanen-Laakso 0.22, 0.7 (320) 
3, 6 James 0.31, 0.62 (321) 
4, 5, 8, 9 Ghafoorunissa 0.6, 0. 7 (318) 
7 Thies 0.65 (322) 
11, 15 Finnegan 1.15, 2.89 (323) 
12 Wallace 1.2 (324) 
13, 17 Li 1.21, 5.5 (325) 
14 Valsta 1.6 (326) 
16 Mantzioris 4.9 (328) 
18 Cunnane 6 (329) 
19 Mest 7.4 (327) 
20, 21 Singer1 13.6 (330) 
22 Beitz 14.7 (331) 
B) 1 Sinclair 0.2 (319) 
2, 6 Seppanen-Laakso 0.22, 0.7 (320) 
3, 4 James 0.31, 0.62 (321) 
5 Thies 0.65 (322) 
7, 11 Finnegan 1.15, 2.89 (323) 
8 Wallace 1.2 (324) 
9 ,  13 Li 1.21, 5.5 (325) 
10 Valsta 1.6 (326) 
12 Mantzioris 4.9 (328) 
14 Cunnane 6 (329) 
15 Mest 7.4 (327) 
16, 17 Singer1 13.6 (330) 
18 Beitz 14.7 (331) 
1 Supplemental values were the same with 20A and 16B representing normolipidemics and 21A and 1 7B representing 
hyperlipidemics. 
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highest ALA group (ALA-3), with no further increase despite increasing EPA 
supplementation 2 and 4 fold (EPA-2, and EPA-3, respectively). Similar trends 
were observed with changes in EPA in erythrocytes (Table 3-8), with dose 
dependent increases in phospholipid EPA. As observed with the plasma 
phospholipid fraction, changes in erythrocyte DHA levels were significantly higher 
in the EPA-1 group, but no additional changes were observed in the higher 
supplemented EPA groups (EPA-2 and EPA-3). 
When the levels of ALA in the background diet doubled (1.2% energy) 
(H-ALA), the changes in tissue EPA content were attenuated in comparison to 
changes in the N-ALA study (Tables 3-7 and 3-8 versus Tables 3-9 and 3-1 0). 
However, tissue levels (in absolute mol%) were comparable following 
supplementation irrespective of the background diet (Table 3-8 compared to 
Table 3-1 0, and Table 3-7 compared to Table 3-9). Interestingly, no changes in 
plasma phospholipid DHA levels were observed with increasing dietary levels of 
EPA when compared to the control group (Table 3-9). Changes in erythrocyte 
phospholipid DHA levels in the lowest supplemented group increased only 5% 
with no further change�s despite increasing levels of EPA in the diet 2 and 4 fold 
(Table 3-1 0). 
Comparison of changes in mouse and human phospholipid fatty acids following 
EPA supplementation 
Comparing our results using pure EPA-ethyl esters to human studies in 
which a combination of EPA+DHA (in the form of fish or fish oil) is the common 
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treatment modality posed a challenge. However, we identified 5 studies with 
human subjects that supplemented only EPA and 6 human studies that 
supplemented only DHA. The impact of both the EPA only and DHA only studies 
on plasma phospholipid EPA (Figure 3-3) and DHA (Figure 3-4) were plotted 
together. Results from these studies indicate that EPA is increased when only 
EPA is supplemented, but to a lesser extent when only DHA is given. Results 
also show that DHA is increased when only DHA is given, but to a lesser extent 
when only EPA is given. We used these observations as a guide when 
determining how to order human studies in which combination EPA + DHA were 
supplemented. When tissue EPA changes were examined, we chose to order 
the studies by increasing content of EPA (rather than total n-3 content). 
Likewise, when DHA changes were examined, we chose to order the studies by 
content of DHA (rather than total n-3 content). 
Percent change in plasma phospholipid EPA in both mouse and human 
supplementation studiE�s is shown in Figure 3-5. Studies are arranged in 
ascending order of the EPA portion of long chain omega-3 fatty acid 
supplementation (Table 3-1 4). When compared to human data, the changes 
observed in the mouse phospholipid EPA levels were dramatically higher when 
the supplemented doses in the N-ALA groups were matched by caloric density. 
However, the responses observed in the mouse diets containing the higher 
background levels of ALA (H-ALA groups) appear to be better correlated with the 
human data with respect to changes in EPA in both plasma and erythrocyte 
phospholipids (Figures 3-5 and 3-6). 
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Figure 3-3: Impact of supplementation with only EPA (pink bars) or only DHA 
(aqua bars) on percent change in plasma/serum phospholipid EPA. Numerical 
superscripts correspond to human study descriptions in Table 3-13. 
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superscripts correspond to human study descriptions in Tablle 3-13. 
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TABLE 3-13 
Human supplementation studies used in Figure 3-3 and 3-4 
Fatty acid Bars in Figs. Author Supplemental Citation 
3-3, 3-4 Energy% ALA 
DHA only 1 ,3 Jensen 0.06, 0.09 (332) 
4 Thies 0.23 (322) 
6 Vidgren 0.6 (333) 
8 Grimsgaard 1 .3 (334) 
1 0  Mori 1 .5 (335) 
1 2  Buckley 2.2 (336) 
EPA only 2 Driss 0.07 (337) 
5,7 James 0.31 , 0.62 (321 ) 
9 Grimsgaard 1 .4 (334) 
1 1  Mori 1 .6 (335) 
1 3  Buckley 2.2 (336) 
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EPA content of total long chain n-3 supplementation (in energy%). Murine data 
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studies intermingled horizontally. Numerical superscripts correspond to human 
study descriptions in Table 3-14. 
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TABLE 3-14 
Human supplementation studies used in Figure 3-5 
Vertical bar Author Supplemental Citation 
in Figure 3-5 Energy% LCPn3 
Total (EPA, DHA, DPA) 
1 Jensen 0.12 (0.02, 0.1) (332) 
2 Finnegan 0.09 (0.03, 0.06) (323) 
3 Engstrom 0.13 (0.05, 0.08) (338) 
4 Wallace 0.15 (0.05, 0.1) (324) 
5 Sinclair 0.12 (0.06,0.01, 0.05) (339) 
6 Driss 0.07 (EPA only) (337) 
7 Ghafoorunissa 0.13 (0.08, 0.05) (318) 
8 Wallace 0.33 (0.1, 0.23) (324) 
9 Vidgren 0.48 (0.11, 0.32, 0.05) (333) 
10 Sinclair 0.64 (0.12, 0.52) (319) 
11 Vidgren 0.41 (0.14, 0.24, 0.03) (333) 
12 Finnegan 0.4 (0.15, 0.25) (323) 
13 Vognild 0.53 (0.19, 0.24, 0.1) (340) 
14 Wallace 0.7 (0.2, 0.5) (324) 
15 Engstrom 0.4 (0.2, 0.2) (338) 
16 Vognild 0.65 (0.22, 0.33, 0.1) (340) 
17 Thies 0.32 (0.23, 0.09) (322) 
18 Hodge 0.51 (0.27, 0.20, 0.04) (341) 
19 Sinclair 0.94 (0.3, 0.64) (339) 
20 James 0.31 (EPA only) (321) 
21 Vognild 0.81 (0.33, 0.45, 0.03) (340) 
22 Sanders 1.24 (0.34, 0.9) (342) 
23 Von Schacky 0.95 ( 0.38, 0.57) (343) 
24 Kew 3.01 (0.38, 2.2, 0.43) (344) 
25 Blonk 0.7 (0.4, 0.3) (345) 
26 Vognild 1.24 (0.45, 0.66, 0.13) (340) 
27 Vognild 1.37 (0.54, 0.77, 0.06) (340) 
28 James 0.62 (EPA only) (345) 
29 Cerbone 1.66 (0.7, 0.96) (346) 
30 Von Schacky 1.92 (0.78, 1.14) (343) 
31 Blank 1.3 (0.8, 0.5) (345) 
32 Singer 2.29 (0.89, 1.4) (330) 
33 Laidlaw 1.8 (1.0, 0.8) (347) 
34 Gronn 2.1 (1.0, 0.9, 0.2) (348) 
35 Stark 1.8 (1.08, 0.72) (349) 
36 Mantzioris 1.5 (1.1, 0.4) (328) 
37 Mantzioris 1.5 (1.1, 0.4) (328) 
38 Gronn 2.4 (1.1, 1.1, 0.2) (348) 
39 Gibney 1.7 (1.2, 0.5) (350) 
40 Stark 2.0 (1.2, 0.8) (351) 
41 Gronn 2.6 (1.2, 1.1, 0.3) (348) 
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TABLE 3-14 
Continued 
Vertical bar Author Supplemental Citation 
in Figure 3-5 Energy% LCPn3 
Total (EPA, DHA, DPA) 
42 Grimsgaard 1.4 (EPA only) (334) 
43 Blonk 2.5 (1.5, 1.0) (345) 
44 Von Schacky 3.82 (1.56, 2.29) (343) 
45 Mori 1.6 (EPA only) (335) 
46 Engstrom 3.32 (2.0, 1.32) (352) 
47 Engstrom 3.32 (2.0, 1.32) (352) 
48 Kew 2.5 (2.1, 0.33, 0.07) (344) 
49 Buckley 2.2 (EPA only) (336) 
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Figure 3-6: Percent change in erythrocyte phospholipid EPA by increasing EPA 
content of total long chain n-3 supplementation (in energy%). Murine data is 
represented by red bars (N-ALA) or red speckled bars (H-ALA), with human 
studies intermingled horizontally. Numerical superscripts correspond to human 
study descriptions in Table 3-1 5. 
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TABLE 3-15 
Human supplementation studies used in Figure 3-6 
Vertical bar Author Supplemental Citation 
in Figure 3-6 Energy% LCPn3 
Total (EPA, DHA, DPA) 
1 Agren 0.3 (.09 , .21 )  (353) 
2 Vidgren 0.48 (0.1 1 ,  0.32, 0.05) (333) 
3 Agren 0.38 (0.13, 0.25) (354) 
4 Vidgren 0.41 (0. 14, 0.24, 0.03) (333) 
5 James 0.31 (EPA only) (321) 
6 Katan 0.40 (0.31 ,  0.06, 0.03) (355) 
7 Sanders 1 .24 (0.34, 0.9) (342) 
8 Von Schacky 0.95 (0.38, 0.57) (343) 
9 Wensing 0. 75 (0.49, 0.26) (356) 
1 0  Palozza 1 .02 (0.57, 0.45) (357) 
1 1  James 0.62 (EPA only) (321)  
12 Katan 0.83 (0.63, 0.1 3, 0.07) (355) 
13  Von Schacky 1 .92 (0.78, 1 .1 4) (343) 
14 Katan 1 .23 (0.94, 0.1 9 ,  0.01) (355) 
1 5  Palozza 2.08 (1 . 1 0, 0.98) (357) 
1 6  Von Schacky 3.85 (1 .56, 2.29) (343) 
17  Palozza 3.1 4 (1 .67, 1 .47) (357) 
1 8  Hagve 2.6 (1 .7, 0 .9) (358) 
3.5 Discussion 
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In 1932, Max Kleiber, pioneer in the field of animal energetics, presented 
an equation that simplified the understanding of interspecies differences in 
metabolic rate: Y= ax¾, where Y is the metabolic rate in kcal, x is bodyweight in 
kilograms, a is the proportionality constant, and ¾ is the scaling exponent and 
the slope of the regression line depicting this relationship (277-279). Further 
characterization and development of interspecies comparison as it relates to 
nutrient intake was present by Rucker (300, 301) and Storm (300), who 
emphasized the need for attention to interspecies metabolic rate differences 
when comparing vitamin and mineral requirements between species. The 
current study is a product of these questions in light of n-3 fatty acid research 
using the rodent model. Historic attempts to linearize and explain interspecies 
differences are applicable not only to metabolic rate and vitamin andmineral 
requirements, but other nutrient components as well. Here, we have tested a 
simple, hypothetical dosing model for adding supplemental n-3 fatty acids to 
rodent diets on the basis of energy %. This model was created based on 
theoretical conclusions of interspecies comparisons previously presented 
(Chapter 2) .  
The driving force of this evaluation is a calculated attempt to achieve 
supplemental doses in the rodent model that offer better predictive value for 
human endpoints. Research examining the relationship between n-3 fatty acid 
supplementation and cancer outcomes is one example where better predictive 
value is needed. Currently, there exists a disparity between the outcomes 
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achieved in human clinical trials with n-3 fatty acids and cell culture or animal 
model studies in cancer research (95). For example, while animal studies 
support a role for n-3 fatty acid effect on colorectal cancer, some human studies 
imply an association (165-167), while others do not (359, 360). We believe that 
one explanation for this inconsistency may be the difference in the amounts of n-
3 fatty acids that are supplemented in animal model experiments versus the 
doses that are given in clinical trials. For example, a literature search of recent 
animal model studies supplementing n-3 fatty acids reveals that when the animal 
doses are translated to human doses on the basis of energy %, n-3 
supplementation ranged from 6-90 gms/day (259-276, 361 ). Doses from the 
majority of these studies would not be compatible with reasonable daily human 
consumption, and therefore, results observed from these studies may not be 
reproducible in humans. 
In the current study, we designed background diets that contained long 
chain PUFA (both n-3 and n-6) that are present in the typical human diet in order 
to compare murine results to archival human trial data. We also used 
supplemental doses that were a reasonable representation of intake that could 
be achieved in humans (670 mg - 3.2 gms/d on the basis of energy%, 
Table 3-4 ). We found that in C57BL/6J mice at these supplemental levels, both 
ALA and EPA significantly increased EPA in both plasma and erythrocytes, with 
EPA supplementation having a greater effect on phospholipid EPA than ALA 
supplementation. DHA, on the other hand, was less influenced by either ALA or 
EPA supplementation and generally increased only when DHA was 
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supplemented (Figures 3-2 and 3-4). In addition, it was found that DHA did not 
increase interminably in response to increasing supplemental DHA doses 
(Figure 3-7). These findings are consistent with animal studies in which 
ALA supplementation increases tissue DHA levels only when ALA content is not 
appreciable in the control diet used for comparison, and further increases in 
ALA dose do not result in dose dependent increases in DHA (ex: (362)). 
We have shown that when n-3 fatty acids are supplemented to rodent 
diets on the basis of energy%, the effect in mice is greater than the effect in 
humans at comparable supplemental energy% (N-ALA background). There are 
several possible reasons for this finding. Hulbert, et al., examined tissues from 
animals over a broad range of size and found that accumulation of 
polyunsaturated fatty acids in several tissues was inversely related to body mass, 
suggesting that tissue from small animals (ex:rodents) would have a higher 
tissue unsaturation index than the same tissue from larger animals (ex:humans) 
(254 ). This may explain why the H-ALA background produced changes that 
better matched archival human changes than the N-ALA background (based on 
total tissue unsaturation). Differences in tissue fatty acid changes may also 
reflect a difference in the capacity for enzymatic conversion of ALA to long chain 
metabolites between rodents and humans (363). The discrepancy between 
rodent and human tissue changes may also suggest that doses derived on the 
basis of caloric density do not produce human equivalent effects. However, if 
these low supplemental doses produce changes that are greater than human 
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TABLE 3-16 
Human supplementation studies used in Figure 3-7 
Vertical bar Author Supplemental Citation 
in Figure 3-7 Energy% LC Pn3 
Total (EPA, DHA, DPA) 
1 Sinclair 0. 12  (0.06,0.01 I 0.05) (339) 
2 Ghafoorunissa 0. 1 3  (0.08, 0.05) (31 8) 
3 Jensen 0.06 (DHA only) (332) 
4 Finnegan 0.09 (0.03, 0.06) (323) 
5 Engstrom 0. 1 3  (0.05, 0.08) (338) 
6 Jensen 0.09 (DHA only) (332) 
7 Thies 0.32 (0.23, 0.09) (322) 
8 Jensen 0. 12  (0.02, 0. 1 )  (332) 
9 Wallace 0. 1 5  (0.05, 0. 1 )  (324) 
1 0  Engstrom 0.4 (0.2, 0.2) (338) 
1 1  Hodge 0.51 (0.27, 0.20, 0.04)  (34 1 )  
12  Thies 0.23 (DHA only) (332) 
1 3  Wallace 0.33 (0. 1 , 0.23) (324) 
14 Vidgren 0.41 (0. 1 4, 0.24, 0.03) (333) 
1 5  Vognild 0.53 (0. 1 9, 0.24, 0. 1 )  (340) 
16  Finnegan 0.4 (0. 1 5, 0.25) (323) 
1 7  Blonk 0. 7 (0.4, 0.3) (345) 
1 8  Vidgren 0.48 (0. 1 1 ,  0.32, 0.05) (333) 
19  Vognild 0.65 (0.22, 0.33, 0. 1 )  (340) 
20 Kew 2.5 (2 . 1 ,  0.33, 0.07) (344) 
21 Mantzioris 1 .5 (1 . 1 ,  0 .4) (328) 
22 Mantzioris 1 .5 (1 . 1 , 0.4) (328) 
23 Vognild 0.81 (0.33, 0.45, 0.03) (340) 
24 Wallace 0. 7 (0.2, 0.5) (324) 
25 Gibney 1 .7 ( 1 .2, 0.5) (350) 
26 Blonk 1 .3 (0.8, 0.5) (345) 
27 Sinclair 0.64 (0. 12, 0.52) (31 9) 
28 Von Schacky 0.95 ( 0.38, 0.57) (343) 
29 Vidgren 0.6 (DHA only) (333) 
30 Sinclair 0.94 (0.3, 0.64) (339) 
31 Vognild 1 .24 (0.45, 0.66, 0. 1 3) (340) 
32 Stark 1 .8 ( 1 .08, 0.72) (349) 
33 Vognild 1 .37 (0.54, 0. 77 I 0.06) (340) 
34 Laidlaw 1 .8 ( 1 .0, 0.8) {347) 
35 Stark 2.0 { 1 .2, 0.8) {351 ) 
36 Sanders 1 .24 {0.34, 0.9) (342) 
37 Gronn 2 . 1  {1 .0, 0.9, 0.2) {348) 
38 Cerbone 1 .66 {0.7, 0.96) (346) 
39 Blonk 2.5 { 1 .5, 1 .0) {345) 
40 Gronn 2.4 (1 . 1 , 1 . 1 ,  0.2) {348) 
41 Gronn 2.6 {1 .2, 1 . 1 ,  0.3) {348) 
42 Von Schacky 1 .92 {0.78, 1 . 14) (343) 
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TABLE 3-16 
Continued 
Vertical bar Author Supplemental Citation 
in Figure 3-7 Energy% LCPn3 
Total (EPA, DHA, DPA) 
A (cont'd). 
43 Grimsgaard 1.3 (DHA only) (334) 
44 Engstrom 3.32 (2.0, 1.32) (352) 
45 Engstrom 3.32 (2.0, 1.32) (352) 
46 Singer 2.29 (0.89, 1.4) (330) 
47 Mori 1.5 (DHA only) (335) 
48 Buckley 2.2 (DHA only) (336) 
49 Kew 3.01 (0.38, 2.2, 0.43) (344) 
50 Von Schacky 3.82 (1.56, 2.29) (343) 
B. 
1 Katan 0.40 (0.31, 0.06, 0.03) (355) 
2 Payet 0.09 (0.008, 0.08) (364) 
3 Katan 0.83 (0.63, 0.13, 0.07) (355) 
4 Katan 1.23 (0.94, 0.19, 0.01) (355) 
5 Agren 0.3 (.09, .21) (353) 
6 Vidgren 0.41 (0.14, 0.24, 0.03) (333) 
7 Agren 0.38 (0.13, 0.25) (354) 
8 Wensing 0.75 (0.49, 0.26) (356) 
9 Vidgren 0.48 (0.11, 0.32, 0.05) (333) 
10 Palozza 1.02 (0.57, 0.45) (357) 
11 Von Schacky 0.95 (0.38, 0.57) (343) 
12 Vidgren 0.6 (DHA only) (333) 
1 3 Sanders 1.24 (0.34, 0.9) (342) 
14 Hagve 2.6 (1.7, 0.9) (358) 
15 Palozza 2.08 (1.10, 0.98) (357) 
16 Von Schacky 1.92 (0.78, 1.14) (343) 
17 Palozza 3.14 (1.67, 1.47) (357) 
18 Von Schacky 3.85 (1.56, 2.29) (343) 
changes in similar endpoints, we feel confident that the differences between 
mouse and human changes in this study are conservative compared to the 
differences that can be expected from supplemental n-3 studies in the general 
literature with even greater doses. 
Dosing on the basis of energy% represents a reasonable method for the 
addition of n-3 fatty acids to rodent studies. Without a current standard for 
supplemental dosing strategies, this study is unique in that it sheds light on the 
gross over-estimation of human response that can be expected from animal 
studies in which large n-3 doses are supplemented. It is also unique in that 
mouse changes were shown to exceed human tissue changes even when long 
chain PUFA (n-3 and n-6) were present in the diet. This further suggests that 
typical rodent studies, in which long chain PUFA are not present in the 
control/background diet, can be expected to overestimate human endpoint 
effects. 
3.6 Conclusions 
While the use of energy% as a dosing model does not precisely predict 
changes in human endpoints, we feel that it establ ishes a guideline for dosing 
that considers interspecies variation inherent in dietary research using animal 
models. In order for rodent studies using supplemental n-3 doses to be 
meaningful, we must reevaluate how doses are selected. It is our hope that by 
offering this vivid comparison between effects in rodents and humans at known 
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supplemental levels, we are offering both a point of reference and a justification 
for change. 
4 SUMMARY AND CONCLUSIONS 
1 0 1 
The establ ishment of a "human equivalent dose" model for n-3 fatty acid 
supplementation is necessary to val idate both past and future fatty acid research 
using animal models. Human equivalent dosing offers a useful pre-clinical 
screening tool for establishing n-3 fatty acid effects in animal models prior to 
investment in larger and more expensive human clinical trials. However, attention 
to dosing "equivalence" is currently not standard in animal studies supplementing 
n-3 fatty acids. In the present study, we have presented a simple and unique 
model for supplementing n-3 fatty acids to rodent diets on the basis of energy%. 
We compared the effects of n-3 fatty acid supplementation on plasma and 
erythrocyte phosphol ipid fatty acids in C57BL/6J mice and archival human 
studies measuring the same endpoints. This allowed us to test the abil ity of 
energy% dosing to predict expected changes in humans. Comparison between 
changes in rodent and human tissues at the same energy% of supplemented 
ALA and EPA showed that murine changes in both plasma and erythrocyte 
phospholipid fatty acids exceeded changes observed in humans. In addition, 
increasing ALA content in the background d iet produced changes in both tissues 
that were more comparable to results seen in humans. While energy% did not 
precisely predict changes in human endpoints, dosing based on energy% 
represents a decrease from supplemental levels that are typically used in rodent 
. . 
studies and therefore offers an improvement to common rodent supplemental n-3 
fatty acid doses. We believe that energy% dosing offers a more conservative 
1 02 
estimate of human endpoint changes than doses that are currently in use. 
Future research is necessary to refine with precision a mathematical model that 
will more closely predict changes in human endpoints. It is our hope that by 
providing these comparisons we wi l l  encourage fatty acid dosing that is based on 
a calculated comparison between humans and animal models. 
1 03 
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Figure A-1: Weekly weights and ending weight of mice in (a) Normal-ALA study 
and (b) High-ALA study. At the start of treatment period, mice in the 
Normal- ALA study were 1 7  days older than the mice in the High ALA study. 
A. 
- 6  
E 5 ftS 
S 4 
� 
ftS 
.E 2 
"C 1 0 
0 
0 
8. 
- 5  
E 
4 
- 3  
� 
J! 2 
C: 
"C 1 
0 
0 
0 
4 9 
0 5 
• • 
14 
Day of Treatment 
10  
Day of Treatment 
1 5  
1 9  
20 
• Control 
• ALA-1 
ALA-2 
X ALA-3 
X EPA-1 
• EPA-2 
+ EPA-3 
• Control 
• ALA-1 
ALA-2 
X ALA-3 
X EPA-1 
e EPA-2 
+ EPA-3 
1 41 
Figure A-2: Daily average food intake for mice in the (a) Normal-ALA study and 
(b) High-ALA study. At the start of treatment period, mice in the Normal-ALA 
study were 1 7  days older than the mice in the High-ALA study. 
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"Failure is not the falling down- but the staying down." - John Keats 
" I  can't go to school to fulfill my dream of becoming an engineer, but I will be the 
best printer that I can be." 
- Harry Wills (my grandfather) 
" I  have fought the good fight, I have finished the race, I have kept the faith." 
II Timothy 4:7 
"It is not that we think that we can do anything of lasting value by ourselves. Our 
only power and success come from God." 
II Corinthians 3:5 
